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Prostate cancer (PCa) is a leading cause of cancer-related morbidity and mortality 
worldwide and especially in developed countries. Clinically, PCa behavior varies from 
indolent, not requiring therapeutic intervention, to highly aggressive, entailing radical 
treatment. Current methods for stratifying PCa aggressiveness are mostly based on the 
Gleason score, serum PSA level and TNM stage, and these are unable to accurately 
predict tumor outcome in an individual basis. Thus, one of the current challenges in PCa 
management is the ability to discriminate indolent from aggressive tumors before 
treatment, avoiding overtreatment and the consequent harms. 
Epithelial to mesenchymal transition (EMT) is a process that allows an epithelial 
cell to acquire a mesenchymal phenotype, and it has been considered a fundamental 
process for tumor invasion and metastization. Taking into account the important role of 
EMT in tumor progression, markers of this process might be used as indicators of tumor 
progression, allowing for a better assessment of tumor aggressiveness. 
Hence, the main goal of this study was to evaluate the expression of EMT-related 
genes in PCa tissue samples and correlate these findings with standard clinical and 
pathological parameters, to unveil new prognostic markers that may improve 
characterization of PCa aggressiveness. 
Using a RealTime ready Custom Panel 384 assay, 93 EMT-related genes were 
assessed in a series of normal prostatic tissues (n=5), stage pT2a+b-PCa (n=5) and stage 
pT3b-PCa (n=5), from which five candidate genes for EMT markers in PCa emerged: 
CAMK2N1, CD44, KRT14, TGFβ3 and WNT5A. 
Expression levels of the five genes were then validated in a larger independent 
series of tissue samples using quantitative RT-PCR. Globally, CAMK2N1, CD44 and 
WNT5A displayed higher expression levels in higher stage and less differentiated PCa. 
These results suggest that CAMK2N1, CD44 and WNT5A expression is associated with 
more aggressive forms of PCa, reflecting a more active transition to an EMT state by 
tumor cells. Further studies, including the evaluation of protein expression by 
immunohistochemistry, are, however, required to validate these preliminary findings in 
larger series of PCa patients and to correlate molecular findings with patient outcome.
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            O cancro da próstata (CaP) é uma das principais causas de mortalidade e 
morbilidade relacionada com o cancro em todo o mundo e especialmente nos países 
desenvolvidos. Clinicamente, o comportamento do CaP pode variar de indolente, onde 
nenhum tratamento é necessário, a altamente agressivo, que implica tratamentos 
radicais. Os actuais métodos de estratificação destes tumores são baseados no score de 
Gleason, nível de PSA e estadio TNM, e não conseguem prever completamente a 
progressão da doença nem a agressividade do tumor. Assim, um dos atuais desafios na 
área do CaP é a discriminação entre tumores agressivos e indolentes antes dos 
pacientes iniciarem qualquer tipo de tratamento, para evitar que estes sejam expostos a 
tratamentos desnecessários e aos efeitos secundários associados. 
A transição epitélio-mesenquimal (TEM) é um processo que permite à célula 
epitelial assumir um fenótipo mesenquimal e tem sido descrita como um processo 
fundamental para a invasão tumoral e metastização. Tendo em conta o importante papel 
da TEM na progressão tumoral, os seus marcadores poderão ser utilizados como 
marcadores de progressão tumoral, permitindo uma melhor avaliação a agressividade 
dos tumores. 
O principal objectivo deste trabalho foi a avaliação da expressão de genes 
relacionados com a TEM em amostras de tecido de CaP e correlacionar os resultados 
com dados clínicos e patológicos, com a finalidade de encontrar novos marcadores de 
prognóstico que possam melhorar a caracterização da agressividade do CaP. 
Utilizando RealTime ready Custom Panel 384 assay foi avaliada a expressão de 
93 genes relacionados com a TEM em amostras de tecido prostático normal (n = 5), CaP 
estadio pT2a+b (n = 5) e CaP estadio pT3b (n = 5), a qual conduziu à selecção de cinco 
genes candidatos para marcadores de TEM em CaP: CAMK2N1, CD44, KRT14, TGFβ3 e 
WNT5A.  
Os níveis de expressão dos cinco genes foram de seguida avaliados numa série 
independente a alargada de amostras através de RT-PCR quantitativo. Globalmente, os 
genes CAMK2N1, CD44 e WNT5A apresentaram níveis de expressão mais elevados nos 
estadios mais avançados e menos diferenciados de CaP. Estes resultados sugerem que 
a expressão de CAMK2N1, CD44 e WNT5A está associada a formas mais agressivas de 
CaP, reflectindo uma maior actividade da TEM nas células tumorais. No entanto, são 
necessários mais estudos, como a avaliação da expressão proteica por 
imunohistoquimica, para validar estes resultados preliminares em séries mais alargadas 
de pacientes com CaP e correlacionar os resultados com a evolução da doença. 
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Prostate Cancer 
 
Prostate Cancer Epidemiology 
 
Prostate cancer (PCa) is the second most frequently diagnosed cancer and the 
sixth leading cause of cancer death in males, accounting for 14% of the total new cancer 
cases and 6% of the total cancer deaths in males in 2008 [1]. 
In Europe, the estimated incidence in 2008 was 370,733 new cases accounting for 
11.6% of all diagnosed cancers (Figure 1) [2]. The same trend was reported for Portugal, 
in which the estimated incidence rate in the same year was of 5,140 new cases 
accounting for 11.9% of all cancers (Figure 1) [2]. 
 
 
Figure 1- Estimated incidence of different types of cancer in Europe and Portugal in 2008, number of newly 
diagnosed cases and proportion of each cancer comparing to all types of cancer (in both genders and 
excluding non melanoma skin cancers). Prostate cancer is represented in lighter green. (Adapted from [2]) 
 
This cancer is one of the most age-dependent cancer, is rare before the age of 50 
increasing exponentially thereafter [3]. 
Incidence rates of PCa vary more than 25-fold worldwide, with the highest rates 
recorded primarily in developed countries of Oceania, Europe, and North America, where 
PCa is the most frequent cancer and the third cause of cancer death in males (Figure 2) 
[1]. This variation is largely due to the wide utilization of prostate-specific antigen (PSA) 
testing in developed countries, that detects clinically important tumors as well as other 
slow-growing cancers that might otherwise escape diagnosis [1]. 
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Figure 2- Estimated age-standardized rates of incidence and 
mortality for prostate cancer (World) per 100,000 [2]. 
 
Mortality rates differ much less, with a 10-fold variation between the countries [2]. 
PSA testing has a much greater effect on incidence than in mortality, leading to a less 
accentuated difference in mortality rates between developed and developing countries [2]. 
In contrast, African descent males in the Caribbean region have the highest mortality rates 
in the world, which is thought to reflect a genetic susceptibility of this group [4,5]. 
Incidence and mortality rates suffered some variations across time, mainly due to   
PSA testing. Before PSA testing implementation, PCa incidence was characterized by a 
high rates in North America, especially for Afro-America men, intermediate rates in 
Europe and low rates in Africa and Asia [3]. After the advent of PSA, the incidence of PCa 
in developed countries remarkably increased, and then fell, but to higher levels than 
previously [3]. Mortality rates have decreased but that changes can be described as 
modest [3]. 
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Prostate Cancer Precursor Lesions 
 
Several lesions have been proposed as precursors of PCa. Adenosis, also known 
as atypical adenomatous hyperplasia (AAH), has been reported, by some authors, as a 
precursor to low-grade transition of PCa, do to some morphological similarities between 
the two lesions [6]. Although, a long-term prospective study showed that men with 
adenosis are not at increased risk for developing PCa [7]. Another lesion that has been 
associated with the development of PCa is proliferative inflammatory atrophy (PIA). In 
fact, there is some molecular and epidemiological as well as some morphological, 
evidence that long-standing PIA may predispose to PCa [8]. However, PIA is a lesion 
frequently identified on biopsy material in the absence of carcinoma and on follow-up has 
not been associated with increased risk of cancer [9]. Therefore, adenosis and PIA should 
not be considered, at present, as direct precursors lesions of PCa.  
Currently, the most well characterized and well established precursor lesion of 
PCa is prostatic intraepithelial neoplasia (PIN). PIN consists of architecturally benign 
prostatic acini lined by cytologically atypical cells, and it is a pathological entity that ranges 
from low- to high-grade (LGPIN and HGPIN) [6]. There is epidemiological, morphological, 
and molecular evidence that HGPIN is a precursor lesion to PCa [6]. A fact that strongly 
supports the association between HGPIN and PCa, is that the prevalence of both HGPIN 
and PCa increases with patients’ age and HGPIN precedes the onset of PCa by a 
decade, approximately [10]. An increased incidence, size and number of HGPIN foci have 
been observed in prostates with carcinoma when compared to prostates without 
carcinoma [10]. Furthermore, several studies have reported that HGPIN, like prostate 
cancer, occurs most frequently in the peripheral zone of the prostate [11]. Genetic 
similarities between these two lesions have also been found, including the loss of 
chromosome 8p and gains of 8q, two of the most frequent genetic alterations occurring 
both in PCa and HGPIN [6]. However, there is evidence that not all PCa arise from 
HGPIN. The majority of prostates with early carcinomas lack any HGPIN [6]. Moreover, 
low-grade carcinomas, especially those present within the transition zone are not closely 
related to HGPIN [6]. Therefore, it appears that HGPIN might be a precursor lesion to 
many, but not all, prostate adenocarcinomas. 
 
 
 
 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
6 
Prostate Cancer Diagnosis 
 
Screening programs based on PSA testing combined with digital rectal 
examination (DRE) have been introduced in some parts of the world, especially in 
developed countries, with main goal of detect early PCa, because only organ confined 
disease can be cured by treatment [12]. However, diagnosis can only be defined based on 
examination of prostate samples [12]. 
The current standard method for detection of prostate cancer is by transrectal 
ultrasound (TRUS) guided core biopsies [13]. The need for prostate biopsies should be 
determined based on PSA level and/or suspicious DRE, concerning patient’s age, 
potential co-morbidities and therapeutic consequences [13]. A positive PSA test, indicative 
for biopsy, is usually defined as a value greater than 3 to 4 ng/mL [14,15]. 
The collected samples should be as far as posterior and lateral in the peripheral 
gland as possible [13]. For a glandular volume of 30-40 ml, 8 to 12 cores are 
recommended and additional cores from suspect areas by DRE/TRUS should be obtained 
[13]. 
The PCa diagnosis is based on histological examination of the collected samples 
[16]. From this analysis, proportion of tumor involvement of the biopsies, number of 
positive biopsies, Gleason score as well as extraprostatic extension, if present, should be 
reported [13,16]. Ancillary techniques, like histochemistry and immunohistochemistry , as 
well as additional sections of the samples should be considered if a suspected glandular 
lesion is identified [16]. 
After diagnosis, based on biopsies evaluation, further diagnostic or staging 
procedures should be used if they might affect the treatment decision [13]. 
 
Histopathological Evaluation of Prostate Cancer 
 
 Gleason Score 
 
Gleason grading system was firstly described in 1966 by Donald F. Gleason and at 
the present, with some changes, it is the most commonly grading system used for PCa, 
being recommended by Word Health Organization (WHO) [17,18]. This grading system is 
based on microscopic assessment of glandular architecture, without consideration of 
nuclear morphology [19]. It recognizes five basic patterns with decreasing of glandular 
differentiation (Figure 3). 
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Figure 3- Updated Gleason grading system for histological grading of prostate cancer. (Adapted from [17]) 
 
Taking into account the heterogeneity of prostate cancer, more than one Gleason 
pattern might be present in the same tumor [19]. Due to this heterogeneity, the  Gleason 
grading is made by a score resulting from the sum of the two predominant patterns in the 
tumor [19]. If the tumor is composed only for one pattern, the Gleason score is obtained 
by doubling the numerical value of this pattern [19]. 
The heterogeneity of prostate cancer also affects the biopsy evaluation, because 
all patterns present in the tumor might not be represented in biopsy cores. A Gleason 
score between 2 and 4 should not be assigned in biopsy samples, due to the risk of 
under-grading the tumor [17]. To decrease the frequency of under-grading, the present 
rules to assess Gleason score depends on the nature of the evaluated sample [17]. 
In clinical practice, Gleason score, along with pathological staging (pTNM staging), 
is one of the most powerful prognostic factors [19]. 
 
Clinical and Pathological Staging 
 
The TNM system is the most important global classification in oncology and is 
used for staging tumors. In TNM system, the extent of the primary tumor (T-category), 
regional lymph nodes involvement (N-category) and distant metastasis (M-category) are 
Pattern 3 - variably sized individual glands, most 
often small sized infiltrating in and among 
benign glands. 
 
Pattern 1 - closely packed   but separate, 
uniform, rounded to oval and medium size 
glands. 
 
Pattern 2 - loosely arranged medium sized 
glands, not quite as uniform as pattern 1. 
Pattern 4 - fused, cribriform or poorly formed 
glands. 
 
Pattern 5 - no glandular differentiation, just 
occasional gland formations are observed. 
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evaluated [20]. Clinical TNM (cTNM) staging is based on information that is available 
without surgery, such as clinical examination, imaging modalities and laboratory tests [20]. 
Pathological TNM staging (pTNM) is based on histological examination of the cancer 
resection specimen [20]. 
This staging system has been adopted by International Union Against Cancer 
(UICC)[20]. The current TNM staging system for PCa is represented in Table 1. 
Concerning that disease anatomic extent is probably the most important prognostic 
factor in oncology, TNM staging is a powerful prognostic factor [20]. As already 
mentioned, Gleason score is also a powerful prognostic factor in PCa, and these two 
factors together have a huge impact in treatment and prognosis. Indeed, there is already 
evidence that TNM staging and Gleason score have independent prognostic value [20]. 
 
Table 1- TNM staging system for prostate cancer. (Adapted from [21]) 
T- Primary tumor 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Clinically unapparent tumor, not palpable or visible by imaging 
T1a Tumor incidental histological finding in 5% of tissue resected during TUR 
T1b Tumor incidental histological finding in more 5% of tissue resected during 
TUR 
T1c Tumor identified by needle biopsy 
T2 Confined within the prostate 
T2a Tumor involves half of the lobe or less 
T2b Tumor involves more than one half of one lobe, but not both lobes 
T2c Tumor involves both lobes 
T3 Tumor extends through the prostate capsule but has not spread to other 
organs 
T3a Extracapsular extension (unilateral or bilateral) 
T3b Tumor invades seminal vesicle(s) 
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles 
T4a Tumor invades bladder neck and/or external sphincter and/or rectum 
T4b Tumor invades levator muscles and/or is fixed to pelvic wall 
N- Regional lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph nodes metastasis 
N1 Regional lymph node metastasis 
M- Distante metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Metastasis at other site(s) 
Abbreviations: TUR- transurethral resection 
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Treatment 
 
Therapeutic management of PCa has become far more complex because of the 
availability of various stage-specific therapeutic options namely active surveillance, 
surgery (radical prostatectomy), radiotherapy and hormonal therapy [22]. Despite all 
therapeutic options available, metastatic disease remains without curative treatment [12]. 
Active surveillance consists in a periodic monitoring with PSA tests, physical 
examinations and repeated prostate biopsy, which is converted to a potentially curative 
treatment at the sign of disease progression, and should be applied in patients with low-
risk PCa (PSA<10ng/mL, Gleason score <7 and stage cT1c to cT2a) [13,23]. This 
therapeutic option was conceived with the aim to reduce the overtreatment of patients with 
low-risk PCa because this tumors usually have a very indolent course even when left 
without treatment [24]. A recent study demonstrated that men with low-risk PCa and with a 
life expectancy over 10 years are good candidates for active surveillance, and only about 
30% of these men will require delayed radical intervention [25]. 
The surgery intervention, radical prostatectomy, is the standard curative treatment 
for PCa, and is the only treatment for localized PCa that proved to reduce mortality and 
metastasis risk when compared to active surveillance [26]. However, for a follow-up over 
10 years, a little or no further increase of benefit has been shown for surgery over active 
surveillance [26,27]. Although, for the subgroup of patients with high-risk PCa (PSA>20 or 
Gleason score 8 to 10 or stage≥cT3a) has been suggested that surgery might reduce 
mortality even for a follow-up above 10 years [13,27]. 
External beam-radiotherapy and brachytherapy are considered alternative 
therapeutical options to radical prostatectomy in patients with disease-free survival rates 
similar to those of surgical procedure [28]. External beam-radiotherapy is also often 
applied for treatment of patients with locally advanced disease and with local failure after 
prostatectomy [12]. Excellent outcomes have been reported for treatment of localized PCa 
with brachytherapy and it has been also suggested as a viable primary treatment option 
for patients with low, intermediate and high-risk localized prostate cancer [29]. 
Being prostate a hormone-responsive organ, hormonal therapy (i.e. androgen 
deprivation) is another therapeutic option available, and it has been the mainstay for 
management of patients with metastatic disease [12]. Although hormonal therapy is 
applied with palliative intent, it might have an important role in mortality impact by delaying 
death from PCa [12]. Due to the hormonal therapy most tumors acquire a hormone-
refractory phenotype, and for these patients the only available option is conventional 
quimiotherapy, which effectiveness still limited [12]. Hormonal therapy may also be 
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applied combined with radiotherapy for treatment of localized or locally advanced disease, 
in order to  improve the outcome [12]. 
Harms and Benefits of PSA Testing 
 
Currently PCa screening is based on measurement of serum PSA levels, but other 
methods of detection, such as digital rectal examination and ultrasunography, are often 
included in screening programs [23]. 
The goal of PCa screening is to reduce deaths due to PCa, increasing length of 
life, and additionally reduce the development of symptomatic metastatic disease [23]. 
There is convincing evidence that PSA-based screening programs result in a 
detection of many cases of asymptomatic PCa [23]. However, the majority of cancer 
detected by screening will never cause symptoms or morbidity and most cancer deaths 
from PCa will not be avoided by screening [30] For these reasons, PSA screening has 
been associated with an “over-diagnosis” [23]. The magnitude of over-diagnosis caused 
by PSA screening is difficult to determine, but two largest trials suggest an over-diagnosis 
rate of 17% to 50% [31]. 
Men with screen-detected cancer can potentially fall into one of the three 
categories [30]: 
 Those whose cancer will result in death despite early diagnosis and treatment; 
 Those who will have good outcomes in absence of treatment; 
 Those whom early diagnosis and treatment improves survival. 
 
The reduction of PCa specific death after screening implementation is, rather 
small. Two of the largest trials of PSA screening, U.S. PLCO (Prostate, Lung, Colorectal 
and Ovarian) and ERSPC (European Randomized Study of Screening for Prostate 
Cancer), aimed to evaluate PSA screening impact in PCa mortality. The USA trial did not 
demonstrate any PCa mortality reduction [32]. The European trial found a reduction in 
prostate cancer deaths of approximately 1 death per 1000 men screened [33].  
PSA test has been also associated with false-positive results, indeed 
approximately 80% of positive PSA test results are false-positive when cutoffs between 
2.5 and 4.0ng/mL are used [15]. False-positive results have been associated with 
negative psychological effects, including persistent worry about PCa, and with frequent 
exposure to additional testing, including one or more biopsies in the following years [34]. 
About one third of the men submitted to prostate biopsy, have experienced pain, fever, 
bleeding, infection and transient urinary difficulties, considering these effects as a 
“moderate or major problem” [35]. 
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The vast majority (about 90%) of men with PSA-detected PCa are early treated by 
surgery, radiation or androgen deprivation therapy [36].  Prostatectomy and radiotherapy 
often cause long-term adverse effects, including urinary incontinence and erectile 
dysfunction, in at least 200 to 300 of 1000 men treated [37]. Prostatectomy have been 
also associated with perioperative mortality (up to 5 in 1000 men will die within 1 month 
after surgery) and radiotherapy have also been associated with bowel dysfunction [37]. 
Conversely, androgen deprivation therapy is associated with erectile dysfunction as well 
as gynecomastia and hot flashes [37]. 
Concerning over-diagnosis associated with PSA screening, man with cancer that 
would remain asymptomatic cannot benefit from screening or treatment. An active 
surveillance, as an alternative of curative treatment is an available option that reduces the 
effects associated with others treatments.However, both physicians and patients tend to 
elect treatments with curative intent, given to the current inability to distinguish tumors that 
will remain indolent from those that will be lethal [38]. Thus, a huge number of men 
harboring PCa that will never become symptomatic are being subjected to the harms of 
treatment. 
 
Discrimination between Indolent and Aggressive Disease - A major 
challenge in prostate cancer management 
 
PCa behavior can vary from indolent, who do not require treatment, to aggressive, 
where radical treatment is required [23]. The current challenge of managing localized PCa 
is to distinguish patients with aggressive tumors from those which tumor do not need any 
intervention. The absence of prognostic factors that could fully predict PCa behavior has 
led to a significant over-treatment of patients who would otherwise require only 
conservative management, exposing then to treatments associated morbidity. Indolent 
PCa refers to a cancer that would never exhibit clinical manifestation according to its 
pathologic features, regardless lifespan of the patient [39]. Currently, from indolent 
tumors, only a proportion of these can be classified as been insignificant PCa, taking into 
account patients’ age and possible comorbidities [39]. The concept of insignificant PCa is 
well established as low-grade, small volume and organ confined PCa that is unlikely to 
progress to clinical and biologic significance [39]. In clinical practice, insignificant PCa is a 
cancer diagnosed in the absence of related symptoms that would not cause mortality or 
morbidity during patients life if left without treatment [39]. To date, the most widely used 
preoperative criteria for predicting insignificant PCa after positive biopsies and before 
surgery are the Epstein criteria. These criteria have emerged in 1994 and in 2004 an 
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update was reported [40]. The updated Epstein criteria to identify insignificant PCa 
consist: 
 PSA density ≤0,15 ng/mL per gram; 
 Gleason score ≤6; 
 Fewer than three positive cores; 
 <50% of cancer involvement in any core. 
 
Although Epstein criteria area useful in insignificant PCa predicting, they might 
lead to a misclassification of about 30% of the patients, who would have unfavorable 
pathological features in prostatectomy specimen [41,42]. Nevertheless, Epstein criteria 
seem to be highly predictive for favorable disease that is cured by surgery, because just a 
small percentage of patients considered to harbor an insignificant PCa demonstrated 
extraprostatic extension in prostatectomy specimens [41,42]. However, predicting 
favorable disease at prostatectomy should not be the main end point of interest, since the 
major goal is to avoid surgery or other treatments, protecting patients from associated 
morbidity. Several preoperative predictive models have emerged in an attempt to better 
identify insignificant PCa. However, the main nomograms reported and validated are just 
slightly superior to Epstein criteria in their ability to predict insignificant PCa, remaining a 
significant number of patients under-staged [39]. 
Hence, to date the current classification of insignificant PCa does not perfectly 
predict the biologic behavior of cancer, and indolent tumors out of this subgroup do not 
have any predictive criteria. Furthermore, there is a need to find more precise and 
replicated tools to better predict the indolent behave of PCa. This challenge in PCa 
management might be addressed by better understanding of the molecular basis of 
cancer progression. 
Epithelial to mesenchymal transition (EMT) is a process that has been associated 
with tumor aggressiveness, playing a central role in tumor invasion and metastasis [43]. 
Thus, molecular markers of EMT can be used as markers of tumor progression in PCa, 
allowing to a better characterization of PCa aggressiveness. 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
13 
Epithelial to Mesenchymal Transition 
 
What is Epithelial to Mesenchymal Transition? 
 
Epithelial to mesenchymal transition (EMT) is a biologic process that allows an 
epithelial cell to undergo multiple biochemical changes enabling it to acquire a 
mesenchymal phenotype, enhancing migratory capacity, invasiveness, resistance to 
apoptosis, and augmenting the production of extracellular matrix (ECM) components 
(Figure 4) [44]. 
 
 
 
Figure 4- Molecular and phenotypic changes in epithelial cells during EMT. EMT involves a functional 
transition of a polarized epithelial cell into a mobile and ECM component secreting mesenchymal cell. During 
this process epithelial cells progressively loose expression of epithelial markers and gain expression of 
mesenchymal markers, while alterations in cell shape are also observed [43]. 
 
During this transition, epithelial cells progressively lose expression of typical 
epithelial markers, such as E-cadherin and keratins, and gain expression of mesenchymal 
markers, including vimentin, α-smooth muscle actin (SMA), and N-cadherin [43,44]. EMT 
is completed when the underlying basement membrane is degraded, allowing for 
mesenchymal cells to migrate away from the original epithelial layer [43]. Importantly, the 
mesenchymal phenotype acquired by EMT is not an irreversible stage, and a 
mesenchymal to epithelial transition (MET) is likely to occur, reconstituting the original 
epithelial phenotype of the cell [43]. 
Distinct molecular processes are associated with EMT and these include activation 
of transcription factors, expression of specific cell-surface proteins, reorganization and 
expression of cytoskeletal proteins, production of ECM degrading enzymes, and altered 
expression of specific microRNAs [43]. 
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Although a common set of genetic and biochemical elements underlie EMT, this 
process may occur in three distinct biological contexts being classified accordingly [43]: 
 Type 1: occurring during implantation, embryogenesis and organ development; 
 Type 2: associated with tissue regeneration and organ fibrosis; 
 Type 3: associated with cancer progression and metastasis. 
 
Briefly, EMT type 1 can generate mesenchymal cells that have potential to 
undergo MET and form secondary epithelia, and it is not associated with an invasive 
phenotype which would result in systemic spread via the circulation [43]. On the other 
hand, EMT type 2 acts as a part of the repair system and normally generates fibroblasts 
and other related cells deemed to reconstruct tissues following trauma and inflammatory 
injury [43]. This type of EMT is associated with inflammation and ceases when 
inflammation is attenuated [43]. In a situation of persistent inflammation, EMT type 2 
continues to respond to ongoing inflammatory stimuli, generating fibrosis and eventually 
leads to organ destruction [43]. Finally, EMT type 3 occurs in cancer cells and endows the 
capacity to invade and metastasize [43]. 
 
EMT and Cancer Progression 
 
The majority of human solid tumors are of epithelial origin, i.e., carcinomas [45]. In 
these tumors, invasion of the basement membrane is thought to be one of the last stages 
of tumor progression, allowing for subsequent metastatic dissemination with life-
threatening consequences [43]. The mechanisms underlying the acquisition of the 
invasive phenotype and the ensuing systemic spread of the cancer cells have been object 
of intensive research. Thus, EMT has been reported as a critical mechanism for invasion 
and metastasis formation in carcinomas [46]. Studies with animal models and cell cultures 
have demonstrated that mesenchymal cancer cells are typically seen at the invasive front 
of primary tumors and these are the cells that eventually enter into subsequent steps of 
invasion and metastization [45]. According to this model, EMT provides mobility to cancer 
cells and the capacity to invade the tissues and organs surrounding the tumor, and also to 
enter the circulation (Figure 5) [43]. After intravasation, these cancer cells are transported 
through the circulation and can leave the blood stream at a remote site where they may 
form metastasis [43]. 
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Figure 5- Contribution of EMT to cancer progression: evolution from carcinoma in situ to invasive carcinoma 
and then to metastatic disease, through EMT and MET. The invasive carcinoma stage involves acquisition of 
mobility by epithelial cancer cells, which may be provided by EMT. EMT endows cancer cells with mobility and 
capacity to invade the tissues and organs surrounding the tumor. The EMT transformed cancer cells also have 
the capacity to enter the circulation and exit the blood stream at a remote site, where they may form 
metastases. Metastasis formation may involve the reversion to the epithelial phenotype, giving rise to a 
secondary epithelial tumor similar to the primary tumor, through the process of MET [43]. 
 
Histologically, metastasis usually resemble the primary tumor from which cells 
arose, thus metastatic cells no longer exhibit the mesenchymal phenotype [43]. This fact 
indicates that metastasizing cancer cells lose their mesenchymal phenotype during 
metastasis formation, probably via MET [45]. The induction of MET in disseminated 
cancer cells likely reflects the microenvironment which they encounter after extravasation 
[46]. Therefore, EMT seems to be an important mechanism for carcinoma progression to 
a metastatic stage and the opposite process, MET, is required for subsequent metastasis 
formation.  
 
Inducing Signals of EMT 
 
The regulation of EMT in cancer cells remains unclear. Genetic and epigenetic 
alterations undergone by cancer cells during tumorigenesis seem to render them 
especially responsive to EMT-inducing heterotypic signals originating in the tumor-
associated stroma [43]. These EMT-inducing signals activate EMT-signaling pathways, 
including transforming growth factor beta (TGFβ), nuclear factor kappa B (NFkB), 
wingless type (Wnt), and Notch which target transcription factors, notably Snail, Slug, zinc 
finger E-box binding homeobox 1 (ZEB1), zinc finger E-box binding homeobox 2 (ZEB2), 
Twist and others (Figure 6) [43,46,47]. Once expressed and activated, each of these 
transcriptional factors can control the complex EMT program, often coupled with other 
transcriptional factors [43]. 
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Figure 6 - Signaling pathways involved in regulation of EMT during tumor progression. 
EMT induction in tumor microenvironment is a complex phenomenon that remains 
unclear. Therefore, the proposed EMT-related signaling pathways are diverse, 
including TGFβ (through Smad-dependent and Smad-independent transcriptional 
pathways), activation of NF-kB signaling, Wnt/β-catenin and Notch signaling pathway, 
among others. These signaling pathways target transcription factors, such as Snail, 
Slug, ZEB1, ZEB2 and Twist, that once expressed and activated can control the 
complex EMT program, often coupled with other transcriptional factors [48]. 
 
Currently, the best studied EMT induction pathway involves TGFβ signaling, which 
is a suppressor of epithelial cell proliferation and has an important role in tumorigenesis 
[49]. However, it is now clear that TGFβ can also act as a positive regulator of tumor 
progression and metastasis [49,50]. Genetic and epigenetic mechanisms work in concert 
to convert TGF-β from a tumor suppressor to a promoter of growth, survival, and 
metastization [50]. 
TGFβ induces EMT in cancer cells through Smad-dependent and Smad-
independent transcriptional pathways [43]. In Smad-dependent pathway, the binding of 
TGFβ results in the formation of TGF-β receptor type I and II tight complexes, which lead 
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to phosphorylation of Smad2 and Smad3 [51]. Phosphorilated Smads form heterodimeric 
complexes with Smad4 and translocate into the nucleus, where they control the 
transcription of target genes related with EMT, through interaction with specific binding 
motifs in their gene regulatory regions, such as Snail, ZEB, Slug and Twist [52]. In Smad-
independent pathway, TGFβ directly activate various types of non-Smad signaling 
pathways that control the transcription of EMT target genes, such as MEK/Ras/Erk, c-Jun 
N-terminal kinase (JNK) and phosphatidylinsitol-3 kinase (PI3K) [53]. 
Another signaling pathway that induces EMT involves NFkB. NF-kB proteins are 
usually sequestered in the cytoplasm in a complex with an inhibitor protein, named IkB 
[54]. The activation of NF-kB is, in most cases, proceeded by the activation of an IkB 
kinase (IKK) complex, wich phosphorylates IkB leading to its degradation and 
consequently to activation of NF-kB [54]. The increased expression of inflammatory 
cytokines (TNF-α, ILs, LPS) in the tumor microenvironment, activates IKKs and 
consequently NFkB pathway [48]. This pathway directly activates the expression of EMT 
inducers, including Snail, ZEB1 and ZEB2 factors [54]. Since NFkB signaling can induce 
EMT in cells unresponsive to TGFβ, the cooperation between TGFβ and NFkB signaling 
pathway may be critical for EMT induction in some cases [55]. 
Wnt/β-catenin and Notch signaling pathways are also important for EMT induction. 
When the Wnt signaling pathway is activated, β-catenin is moved to the nucleus, and such 
accumulation is often associated with loss of E-cadherin expression and with susceptibility 
to enter in EMT [46]. Concerning the Notch signaling pathway, it has been reported that 
Slug is a direct target of this pathway, which is one of the EMT transcription factors [56]. 
These two signaling pathways contribute to EMT induction and have also been reported 
as important for the maintenance of the stemness of cancer stem cells [57,58]. TGF-β and 
Wnt signaling pathways may collaborate to induce EMT and thereafter function in an 
autocrine fashion to sustain the resulting phenotype [59]. 
Epigenetic mechanisms seem also to be also involved in EMT regulation. These 
mechanisms, unlike mutations, can be reversed, which is consistent with the reversible 
nature of EMT. Indeed, an epigenetic regulation of E-cadherin during EMT and MET has 
been already suggested [60]. Noncoding microRNAs have been reported as components 
of the cellular signaling pathway that regulates EMT. MicroRNA-200 (miR-200) inhibits the 
expression of ZEB1 and ZEB2, resulting in an increase of E-cadherin expression, thereby 
contributing to the maintenance of the epithelial phenotype [61,62]. In breast carcinoma, 
loss of miR-200 correlates both with increased vimentin and decreased E-cadherin 
expression [62]. MicroRNA-21 has the opposite role and is up regulated in many cancers, 
facilitating TGF-β-induced EMT [63]. 
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EMT and Cancer Stem Cells  
 
Cancer stem cells (CSCs) are often compared with normal stem cells, which are 
multipotent or pluripotent progenitor cells that can self-renew and endure asymmetric cell 
division, to give rise to differentiated or committed progenitors [64]. CSCs are cancer cells 
that exhibit a stem cell–like phenotype and which are capable to reconstruct the 
heterogeneity of the originating tumor [65]. 
The first evidence of CSCs came in 1997 through studies on acute myeloid 
leukemia, where a subpopulation of CD34+/CD38- cells with the ability to initiate tumor 
growth was identified [66]. More recent studies have also identified CSCs in brain tumors 
(CD113+)[67], breast cancer (CD44highCD24lowESA+)[68], oral squamous cell 
carcinoma (CD44high)[69], pancreatic cancer (CD44+CD24+ESA+)[70], prostate cancer 
(CD44+)[71] and in many other carcinomas. 
Due to those characteristics and also to the fact that metastases often recapitulate 
the organization of the primary tumor, it is believed that CSCs in association to EMT play 
a major role in tumor dissemination [72]. 
As previously mentioned, a decisive step in tumor progression is the induction of 
EMT in tumor cells, including CSCs. It has been suggested that CSCs undergo EMT, 
acquiring the capacity to migrate out of primary tumor and colonize distant sites, where 
they may undergo MET to establish metastases with the same features of primary tumor ( 
Figure 7) [72]. Therefore, according to this model, CSCs play a central role in this 
process, being the main responsible for tumor metastization, which may explain the 
similarity observed between primary tumor and respective metastases. 
Supporting this model, recent studies have suggested that CSCs are capable to 
undergo EMT and the reverse process MET, switching between a mesenchymal and an 
epithelial phenotype [73]. However, not all cancer cells exhibiting EMT features are cancer 
stem cells, as some cells that undergo EMT do not have the ability to reverse the process 
through MET and become fixed in a mesenchymal phenotype, representing a more 
differentiated EMT stage [73]. The role of this population of cells in tumor progression is 
unknown, but it is possible that they may make an important contribution to the tumor 
stroma [74]. Studies have also demonstrated that metastatic cancer cells, that presumably 
underwent EMT, exhibit a CSC phenotype [68,75]. 
Some authors provide a different interpretation of the CSCs / EMT connection, 
associating EMT with induction of a CSCs phenotype in cancer cells [65]. This association 
is supported by the fact that Wnt and Noch pathways, which are involved in EMT 
regulation, also drive both normal and CSC renewal and maintenance [57,58]. 
As well as being implicated in metastasis formation, CSCs that have undergone 
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Figure 7- Metastasis formation involving CSCs: a model of metastatic dissemination with a 
central role for CSCs is depicted. CSCs can undergo EMT, acquiring the capacity to migrate 
out of the primary tumor and reach the circulatory and lymphatic systems, through which 
they can travel to distant sites. Once arriving at the distant sites, these cells can undergo 
MET to resume their proliferative phenotype and produce a metastasis. A sub-population of 
EMT-CSCs do not have the ability to undergo MET and become fixed in a mesenchymal 
phenotype. The role of these cells is unknown, but it is possible that they may contribute to 
tumor stroma [74]. 
  
EMT are also associated with therapeutic resistance. Cancer therapies are usually 
capable to kill bulk tumor cells but often spare CSCs, which are then responsible for tumor 
recurrence after an apparently successful therapy [74]. Clinically, recurrence often results 
in a more aggressive tumor, possibly due to a higher content of CSCs [74]. The 
mechanism underlying the therapeutic resistance of CSCs is not fully understood. 
However, drug efflux transporters of the ABC family have been implicated in therapeutic 
resistance of CSCs [74]. Therefore, CSCs that have undergone EMT are now an 
important focus of research aimed at preventing tumor metastasis and recurrence. 
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Evidence of EMT in Prostate Cancer Progression  
 
Over the last years, EMT has been an area of intensive research in PCa, and one 
of the most controversial aspects is the extent to which one can find evidence of EMT in 
human pathological specimens [76]. In PCa, the Gleason score might be viewed as 
morphological evidence of EMT. An increasing Gleason score is associated with a 
progressive loss of epithelial glandular architecture, including loss of defined basement 
membrane and cell polarity, and with augmented invasive patterns, like cell cords, sheets 
or individual cells invading tumor stroma [77]. Further evidence of EMT is delivered from 
analysis of molecular markers of this process. Concerning the metastasis model 
previously mentioned, changes in the expression of EMT-associated genes should be 
evident in primary tumors and the regression of these alterations must be evident in 
metastatic lesions. 
Numerous studies have been performed to evaluate the expression levels of E-
cadherin in PCa specimens. A decreased of E-cadherin expression correlates with higher 
Gleason score and more advanced pathologic stage [78,79]. Regarding metastasis, some 
studies report a decrease of E-cadherin expression in bone and lymph node metastasis 
and others clearly show unchanged expression [78,79]. Concerning an epigenetic 
regulation for E-cadherin expression, a study using PCa specimens reported that 
methylation of the E-cadherin gene is common in prostate cancer and that the density of 
E-cadherin promoter methylation correlates with tumor progression [60]. In PCa cell lines, 
derived from bone metastasis, an unmethylated state of E-cadherin was found, 
corresponding to a re-expression of the protein [80]. Despite these results, definitive 
molecular evidence of MET in PCa metastases has not emerged yet. 
In contrast to E-cadherin, markers of mesenchymal phenotype, like N-cadherin, 
are up-regulated in more aggressive tumors. A recent study showed that N-cadherin is up-
regulated in castration-resistant PCa, both in animal models and in human specimens, 
and it is also associated with metastatic disease and higher Gleason score [81]. The up-
regulation of this cadherin has been also reported as a major cause of PCa metastasis 
formation and castration resistance [82]. 
Transcriptional regulators of EMT have drawn most of the attention because they 
are arguably the best diagnostic markers of EMT to date [83]. Much of what has been 
reported about EMT in prostate cancer, as well in other cancers, is based on studies using 
in vitro and in vivo models. TGFβ is an inducer of EMT and has been one of the most 
studied EMT pathways. The capacity to induce EMT-like states in PCa cells lines has 
been shown by a number of research teams. TGFβ induced EMT in PCA cells lines is 
mediated by NFκB, which accumulates in the nucleus, inducing vimentin expression [84]. 
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In tissue samples, the expression of TGFβ, NFκB and vimentin has been correlated with 
tumor recurrence following surgery [84]. 
Recent studies suggest an interesting role for DOC-2/DAB2 interacting protein 
(DAB2IP) in PCa EMT. This gene is frequently down-regulated by epigenetic mechanisms 
in PCa [85] and this inhibition has been associated, in PCa cells an xenograft models, with 
induction of EMT, with DAB2IP involved in Wnt signaling modulation, and development of 
metastases [86]. The involvement of the Wnt signaling pathway in PCa EMT has been 
also reported. Over-expression of Wnt antagonists, secreted Frizzled related proteins 
(sFRPs) or Wnt inhibitory factor 1 (WIF1), in PCa cells results in increased expression of 
epithelial markers, decreased invasiveness and down-regulation of SNAIL2 and TWIST 
[87,88]. A recent study has also unveiled a connection between TMPRSS2-ERG gene 
fusions and Wnt pathway activation, as ERG may drive the expression of the Wnt receptor 
Frizzled 4 (FZD4), which is required for expression of a number of EMT markers [89]. 
Taking into account the role of androgen receptor (AR) in PCa progression, it is not 
surprising that AR signaling has also been implicated in EMT induction. In PCa cell lines, 
androgens may induce an EMT pattern through Snail activation, leading to significant 
changes in cell migration and invasion potential [90]. Expression levels of AR are 
inversely correlated with androgen-mediated EMT, indicating that a low AR content is 
required for the EMT phenotype, whereas a decrease of androgen-mediated EMT with 
over-expression of AR has been observed [90]. 
Transcriptional factors including members of the Snail, Twist and ZEB families 
have also been reported to be involved in EMT in PCa. SNAIL1 represses E-cadherin 
gene expression as well as that of Raf kinase inhibitor protein (RKIP), which has been 
identified as a metastasis suppressor in PCa [91]. Moreover, TWIST1 induces EMT-like 
stages in PCa cells, including up-regulation of N-cadherin [92] and ZEB1 is a direct 
suppressor of E-cadherin in PCa cell lines, facilitating transendothelial migration [93]. 
Currently, there is wide evidence that EMT-like states do exist and are important 
for PCa progression and metastasis formation. However, there is no compelling evidence 
of EMT as a reversible transdifferentiation mechanism in response to local inductive 
stimuli, which might account for the routine pathological findings. 
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Taking in consideration the important role of played by EMT in tumor progression 
and metastasis formation, the markers of this process might be used as indicators of 
tumor aggressiveness, allowing for improved PCa patients’ management. 
 
Hence, the aims of this study are: 
 
 Identify EMT-related genes that might be relevant for PCa progression. 
 
 Evaluate expression levels of the EMT-related genes in PCa tissue samples. 
 
 Correlate the expression levels of EMT-related genes with standard clinical 
and pathological parameters routinely used to assess tumor aggressiveness. 
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Clinical Samples 
 
All samples used for the purpose of this Thesis were collected at Portuguese 
Oncology Institute-Porto, Portugal between 2001 and 2012, and included 97 prostate 
adenocarcinoma (PCa) samples prospectively collected from patients with clinically 
localized disease consecutively diagnosed and treated with radical prostatectomy. 
Simultaneously, in 49 radical prostatectomy specimens, prostatic intraepithelial neoplasia 
(PIN) lesions distant to the tumor were also identified and collected. 
Additionally, five samples of prostate cancer metastasis (MET) from brain, bone, 
lymph node, glans and omentum were also included in our study. As controls, 16 samples 
of normal prostatic tissue (NPT) were collected from peripheral zone of prostates obtained 
from cystoprostatectomy specimens of bladder cancer patients that did not harbor PCa. In 
an attempted to increase the series of non-neoplastic samples were also evaluated 14 
samples of benign prostatic hyperplasia (BPH) collected by transurethral resection (TUR).  
All tissue samples, excepted metastasis, were promptly frozen immediately after 
the surgery and stored at -80ºC for further analysis. After histological identification of PCa, 
PIN, NPT and BPH by an experienced pathologist (Rui Henrique, M.D., PhD), fresh-frozen 
tissue fragments were trimmed to maximize the yield of target cells (>70% of target cells). 
Subsequently, an overage of fifty 12µm thick sections were cut and at the end a section 
was stained to ensure a uniform percentage of target cells and to exclude contamination 
from neoplastic cells in normal tissues. Metastatic samples were obtained from formol 
fixed and paraffin embedded tissues. 
Gleason score and TNM stage of all cases of PCa were previously assessed by 
histological slides from formalin-fixed, paraffin embedded tissues fragments from the 
same surgical specimens. Relevant clinical data was collected from clinical charts. 
This study, as well as the use of samples and the access to clinical data, was 
approved by the institutional review board (Comissão de Ética) of Portuguese Oncology 
Institute – Porto, Portugal. 
 
Evaluation of Expression of EMT-Related Genes in Prostate 
Cancer  
 
Based on an intensive literature review, 93 potential EMT-related genes were 
selected for gene expression evaluation in prostate cancer samples (Annex 1). 
Concerning those genes, we started by accessing the mRNA expression using a specific 
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platform and the best genes were selected for validation on a large number of 
independent samples. 
 
RNA Extraction 
 
Total RNA from all clinical samples, except from metastasis samples, was 
extracted using a trizol method. Briefly, 1500µL of Trizol® Reagent (Invitrogen, Carlsbad, 
CA, USA) was added to each 2.0mL tube and tissues were homogenized using rotor-
shaker. Tubes were incubated for 5 to 10min at room temperature and then 300µL of 
Chloroform (Merck, Germany) were added. The tubes were vigorously hand shacked for 
15 sec and incubated for 3min at room temperature followed by a 15min 12000g 
centrifugation at 4ºC. Then, 600µL of the upper phase of each tube, phase containing 
RNA, was transferred to a new tube. RNA was purified using the PureLinkTM RNA Mini 
Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.  
Since MET samples were formol fixed and paraffin embedded (FFPE), their RNA 
extraction was performed using High Pure FFPE RNA Micro KIT v.7 (Roche Applied 
Science, Mannhein, Germany), according to the manufacturer's instructions. 
RNA concentration and purity ratios were then evaluated using NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, USA). Aditionally, RNA quality was 
checked by ectrophoresis in a 2% agarose gel. 
 
cDNA Synthesis  
 
To performed the screening of the 93 EMT-related genes, cDNA was synthesized 
from 1000ng of total RNA by reverse transcription using Transcriptor High Fidelity cDNA 
Synthesis Kit v.6 (Roche Applied Science, Mannhein, Germany), according to 
manufacturer's instructions.  For the validation of the firstly identified differentiated 
expressed genes by QRT-PCR, 300ng of total RNA were used to synthesize and amplify 
cDNA using TransPlex® Whole Transcriptome Amplification (WTA) Kit (Sigma-Aldrich®, 
Germany) according to manufacturer’s protocol. WTA reaction products were purified 
using QIAquick PCR Purification Kit (QIAGEN, Germany), according to manufacturer’s 
protocol, and stored ate -20ºC. 
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Screening of 93 EMT-Related Genes Expression 
 
Expression levels of 93 EMT-related genes previous selected were evaluated in 
NPT (n=5), pT2a+b-PCa (n=5), pT3b-PCa (n=5) and MET (n=5) samples using a 
RealTime ready Custom Panel 384 assay (Roche Applied Science, Mannhein, Germany). 
This experiment was performed in triplicates for PCa samples and without replicates for 
NPT and MET. 
Additionally to the 93 selected genes RealTime ready Assays pre-plated and dried-
down, a custom panel of three reference genes, GUSβ, TFRC and RN18S1, were also 
included. GUSβ and TFRC have been reported as two of the most suitable genes to be 
used as reference genes in QRT-PCR assays in prostate tissue samples [94]. Since the 
RealTime ready Custom Panel 384 assay had three wells available for reference genes, 
we also add RN18S1, which is one of the most commonly used reference genes in this 
type of analysis in a variety of tissue samples [95,96]. 
The RealTime ready Assays are based on Universal ProbeLibrary (UPL) 
technology, which are short hydrolysis probes, labeled at the 5’ end with a reporter dye 
(FAM) and at the 3’ with a dark quencher dye. These probes, in order to maintain the 
specificity and melting temperature, have a Loked Nucleic Acids (LNA) incorporated into 
sequence.  
In each well 0.1μL of cDNA (corresponding to 5ng), 5 μL of LightCycler® 480 
Probes Master v.9 (Roche Applied Science, Mannhein, Germany) and 4.9μL LightCycler® 
480 Probes Master H2O (included in LightCycler® 480 Probes Master v.9) were added. 
The QRT-PCR reaction was performed in a RealTime termocycler LightCycler® 480 II 
(Roche Applied Science, Mannhein, Germany), following manufacturer's instructions. 
 Expression levels of the 93 genes were analyzed using the comparative Ct method 
(∆∆Ct), which is suitable when a high number of  genes are analyzed [97]. The ∆∆Ct 
method was applied according to the following expressions:  
 
Difference of expression between two groups = 2-ΔΔCt 
ΔΔCt = MedianΔCt (group A) – Median ΔCt (group B) 
ΔCt = Ct (gene of interest) – Ct (reference gene) 
 
 In order to calculate ∆Ct, the most constant endogenous control and 
simultaneously the control that amplified in all samples was selected. It was considered a 
significant reduction of expression values of 2-∆∆Ct bellow 0.5 and a significant increase of 
expression values of 2-∆∆Ct above 2.0.  
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 From the 93 EMT-related genes analyzed, five genes were selected as potential 
markers of EMT in PCa based on the following criteria: 
 Higher differences of expression between (in order of importance): 
o  pT3b-PCa and NPT 
o  pT3b-PCa and pT2a+b-PCa 
 Correlation between gene behavior in the analysis and described literature. 
 
Evaluation of Selected Genes Expression Levels in a Largest 
Independent Series  
 
In order to validate previous results, expression levels of genes selected were 
evaluated in a largest independent series of NPT (n=16), HBP (n=14), PIN (n=49), 
pT2a+b-PCa (n=50) and pT3b-PCa (n=47) samples. For that were used TaqMan® Gene 
Expression assays (Applied Biosystems, Foster City, CA, USA) for the selected genes 
and for the endogenous controls GUSβ and TFRC. 
This assay comprise a unlabeled PCR primer pair and a TaqMan® probe with a 
reporter FAMTM dye label and a minor groove binder (MGB) linked to the 5’ end and a 
nonfluorescent quencher (NFQ) on the 3’ end. The quantitative QRT-PCR reaction 
performed using TaqMan® assays is based on the 5’ nuclease activity of the Taq DNA 
polymerase. During QRT-PCR, TaqMan® probes hybridize to the target DNA between the 
two unlabeled PCR primers. Signal from the fluorescent dye on the 5’ of TaqMan® probes 
is quenched by NFQ on its 3’ end through fluorescence resonance energy transfer 
(FRET). A Taq polymerase extends the unlabeled primers using the template strand as a 
guide. When the polymerase reaches the TaqMan® probe, it cleaves the molecule, 
separating the dye from the quencher, and allowing it to fluoresce. The QRT-PCR 
instrument detects fluorescence from the unquenched FAMTM dye. With each cycle of 
PCR, more dye molecules are releases, resulting in an increase in fluorescence intensity 
proportional to the amount of amplicon synthesized. 
The QRT-PCR assay was performed in 96-well plates on an Applied Biosystems 
7500 Real-time PCR system (Applied Biosystems, Foster City, CA, USA), according to the 
recommended protocol. Briefly, in each well was added 2µL of WTA-cDNA diluted sample 
(dilution factor of 5x), 1µL of TaqMan® Gene Expression assay, 12.5µL of TaqMan® 
Universal PCR Master Mix and 9.5µL (Applied Biosystems, Foster City, CA, USA) of 
bidestilated water (B.BRAUN, Melsungen, Germany). The QRT-PCR conditions were the 
recommended by the manufacturer: 50ºC for 2 min, 95ºC for 10 min, 40 cycles at 95ºC for 
15 sec and 60ºC for 1 min.  
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All samples were run in triplicate and two water blanks were added to each plate 
as negative controls. WTA-cDNA synthesized from prostate total RNA was used to 
prepare five consecutive cDNA dilutions (dilution factor of 10x) that were analyzed as 
standards, allowing the construction of a standard curve for relative quantification and 
PCR efficiency assessment.  
The expression levels were analyzed using the relative standard curve method, 
which provides more accurate quantitative results in comparison with the ∆∆Ct method 
[97]. The results from the QRT-PCR were analyzed using the 7500 Software version 2.0.5 
(Applied Biosystems, Foster City, CA, USA). In each sample, the mean quantity of each 
gene was normalized with mean quantity of endogenous controls GUSβ and TFR, 
according to the expression: 
 
 Gene expression =   
 
 
Statistical Analysis 
 
Differences in expression levels of the EMT-related genes between the different 
groups of samples (NPT, BPH, PIN, pT2a+b-PCa and pT3b-PCa) were firstly analyzed 
using Kruskal-Wallis nonparametric test, followed by nonparametric Mann-Whitney U-test, 
when appropriate. 
The association between expression levels of EMT-related genes and Gleason 
score was also evaluated using the Kruskal-Wallis and Mann-Whitney-U tests. A 
nonparametric Spearman test was performed to assess a correlation between expression 
levels and PSA and age.  
All tests were two-sided and p-values were considered significant when inferior to 
0.05. For multiple comparisons, Bonferroni’s correction was used to adjust p-values. 
Statistical analysis was performed using the software IBM® SPSS® Statistics 20. 
 
                   Gene Mean Quantity                   2 
GUSβ Mean Quantity + TFR Mean Quantity 
2 
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Clinical Samples 
 
For the purpose of this study, tissue samples of normal prostate tissue (NPT, 
n=16), benign prostatic hyperplasia (BPH, n=14), high-grade prostatic intraepithelial 
neoplasia (PIN, n=49), prostate adenocarcinoma (PCa, n=97), and prostate cancer 
metastasis (Met, n=5) were used to evaluate the transcript levels of EMT-related genes. 
Relevant clinical and pathological data of the patients included on this study are 
summarized in Table 2.  
 
Table 2- Clinical and pathological features of patients included in this study 
Clinicopathological 
Features 
NPT BPH PIN PCa Met 
Patients, n 16 14 49 97 5 
Median Age, yrs  
(range) 
63 
(45-80) 
67 
(61-74) 
65 
(51-75) 
63 
(50-75) 
73 
(65-89) 
PSA (ng/mL), median 
(range) 
n.a. 
4 
(1.0-22.0) 
n.a. 
9.1 
(3.0-24.7) 
n.a. 
Pathological Stage, n (%)      
pT2a+b n.a. n.a. n.a. 50 (52) n.a 
pT3b n.a. n.a. n.a. 47 (48) n.a 
Gleason Score, n (%)      
<7 n.a. n.a. n.a. 27 (28) n.a 
=7 n.a. n.a. n.a. 56 (57) n.a 
>7 n.a. n.a. n.a. 14  (15) n.a 
Abbreviations: Normal prostatic tissue (NPT), benign prostatic hyperplasia (BPH), high-grade prostatic 
intraepithelial neoplasia (PIN), prostate cancer (PCa) and not available/applicable (n.a.). 
 
Screening of 93 EMT-Related Genes’ Expression 
 
After analyzing expression levels of the 93 EMT-related genes according to criteria 
previously described, CAMK2N1, CD44, KRT14, TGFβ3 and WNT5A were identified as 
differentially expressed in PCa (Table 3 and Table 4). Results for the 93 EMT-related 
genes analyzed are discriminated in Annex 2.  
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Table 3- Values of 2
-ΔΔCt
 between pT3b-PCa and NPT, and between pT2a+b-PCa and pT3b-
PCa for the selected genes. 
 2
-ΔΔCt 
Target Name pT3b-PCa Vs. NPT pT3b-PCa Vs. pT2a+b-PCa 
CD44 0.16 0.31 
KRT14 0.19 0.28 
TGFB3 0.21 0.26 
WNT5A 2.68 9.16 
CAMK2N1 4.76 4.04 
 
 
Table 4- Variation of expression of the five selected genes between the three groups of samples. 
Variation of Expression 
CD44 KRT14 TGFB3 WNT5A CAMK2N1 
     
 
Legend: - decrease of expression; - increase of expression 
 
CD44 is involved in a variety of process including cell adhesion and has been 
recently proposed as a CSC marker, namely for PCa stem cells [71,98]. Both tumor 
suppressive and oncogenic functions have been suggested for CD44 [99,100]. Thus, both 
an increase or a decrease of expression with tumor progression could be expected. In this 
first analysis was observed a decrease in expression with tumor progression, supporting a 
tumor suppressive role for CD44. 
CAMK2N1 encodes for a protein that inhibits CAMK2 activity, and this inhibition 
has been associated with a reduction of proliferation and invasion capacities [101]. 
Indeed, a recent study in PCa tissue samples has reported a higher expression of 
CAMK2N1 in more aggressive tumors [102]. Our preliminary results suggested a 
decreased expression of CAMK2N1 with tumor progression, corroborating the previously 
reported results.  
WNT5A encodes a ligand that can activate the Wnt pathway, which has been 
associated with EMT induction in tumor cells [43]. Thus, an increased expression with 
tumor progression would be expected. At this point, our results revealed an inconsistent 
variation of expression (Table 4), but a similar behavior has been already reported [103]. 
TGFβ3 encodes for a ligand that can activate the TGF-β signaling pathway, which 
has been associated with EMT induction. This signaling pathway, however, has been also 
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reported as tumor suppressive [43,49]. Thus, either an increase or a decrease of TGFβ3 
expression with tumor progression could be anticipated. In this first analysis a decrease of 
expression with tumor progression was observed, supporting a tumor suppressive role for 
TGFβ3. 
KRT14 encodes for a keratin protein, which is a major component of the epithelial 
cells’ cytoskeleton [104]. During EMT, epithelial cells progressively loose expression of 
typical epithelial markers, such as keratins, and, thus, a decrease of KRT14 expression 
with tumor progression would be expected [43], and this corresponded to to our 
observations 
Other genes have demonstrated significant differences in expression (e.g., VCAN, 
COL5A2 and PROM1) but the variations of expression observed were not consistent and, 
thus, further analyses were not carried out. 
The results of metastasis samples were not further analyzed because a significant 
number of genes did not adequately amplify. In line with these findings, the evaluation of 
metastasis’ RNA quality by electrophoresis demonstrated poor quality (data not shown). 
 
Evaluation of Selected Genes Expression Levels in a Largest 
Independent Series  
 
Expression levels of the five EMT selected genes were analyzed in a larger and 
independent series of NPT (n=16), BPH (n=14), PIN (n=49), pT2a+b-PCa (n=50) and 
pT3b-PCa (n=47). BPH samples were used in an attempt to increase the series of non-
neoplastic samples, but statistically significant differences were observed for expression 
levels of the majority of the analyzed genes between BPH and NPT. Thus, BPH samples 
were excluded from further analysis. 
No correlations were found between expression levels of any of the EMT-related 
genes and serum PSA levels or age of PCa patients. Regarding Gleason score, analysis 
of variance identified significant differences in the expression levels of CAMK2N1, CD44 
and WNT5A among Gleason score groups (<7, =7 and >7), and increased expression 
levels were depicted for tumors with higher Gleason score (Figure 8, Figure 9 and Figure 
10). Comparing expression levels using Mann-Whitney U-test (MW), only CAMK2N1 and 
WNT5A displayed significant differences among all three groups (Figure 8 and Figure 10). 
Analysis of variance also identified significant differences in CAMK2N1, CD44 and 
WNT5A expression levels among NPT, pT2a+b-PCa and pT3b-PCa. In locally advanced 
tumors (pT3b-PCa), CAMK2N1 expression levels were significantly higher than those of 
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organ-confined tumors (pT2a+b-PCa) or in NPT (Figure 11). However, no statistically 
significant differences were observed between the latter two groups. 
 
 
Figure 8 - Relative expression levels of CAMK2N1 with tumors Gleason score. 
 
 
Figure 9 - Relative expression levels of CD44 with tumors Gleason score. 
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Figure 10 - Relative expression levels of WNT5A with tumors Gleason score. 
 
 
 
Figure 11- Relative expression levels of CAMK2N1 in NPT, pT2a+b-PCa and pT3b-PCa. 
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Likewise, CD44 expression levels were significantly higher in advanced stage PCa 
cases in comparison with organ-confined tumors, but no significant differences were 
observed between NPT and pT2a+b-PCa or pT3b-PCa (Figure 12). Surprisingly, both 
NPT and pT3b-PCa displayed significantly higher WNT5A expression levels compared to 
those of pT2a+b-PCa, and no significant differences were observed between NPT and 
pT3b-PCa (Figure 13). 
 
 
Figure 12- Relative expression levels of CD44 in NPT, pT2a+b-PCa and pT3b-PCa. 
 
Contrarily, for KRT14 and TGFB3, no significant differences in expression levels 
were observed among the different groups of tissue samples (NPT, pT2a+b-PCa and 
pT3b-PCa) (Figure 14 and Figure 15). 
Additionally, the expression levels of the same genes were also assessed in the 
pre-malignant lesions of the prostate (PIN). A considerable heterogeneity was apparent 
for the expression levels of almost all genes in PIN lesions (data not shown). For 
CAMK2N1, expression levels observed in PIN lesions were significantly higher than those 
observed in NPT and pT2a+b-PCa. Nonetheless PIN lesions displayed significantly lower 
levels than locally advanced tumors (Figure 16). CD44 expression levels in PIN samples 
were significantly higher than those observed in any other group of samples (NTP, 
pT2a+b-PCa and pT3b-PCa) (Figure 17). Contrarily, PIN samples showed significantly 
lower WNT5A expression levels compared to NPT and pT3b-PCa, but the same trend 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
    
43 
was not found for organ-confined tumors. Indeed, no significant differences were 
observed between PIN and pT2a+b-PCa (Figure 18). 
 
 
Figure 13- Relative expression levels of WNT5A in NPT, pT2a+b-PCa and pT3b-PCa. 
 
 
Figure 14- Relative expression levels of KRT14 in NPT, pT2a+b-PCa and pT3b-PCa. 
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Figure 15- Relative expression levels of TGFβ3 in NPT, pT2a+b-PCa and pT3b-PCa. 
 
 
 
 
Figure 16- Relative expression levels of CAMK2N1 in NPT, PIN, pT2a+b-PCa and  
pT3b-PCa. 
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Figure 17- Relative expression levels of CD44 in NPT, PIN, pT2a+b-PCa and pT3b-PCa.  
 
 
 
Figure 18- Relative expression levels of WNT5A in NPT, PIN, pT2a+b-PCa and       
pT3b-PCa 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
46 
 
. 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
    
47 
Discussion
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
48 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
    
49 
Prostate cancer is the second most frequently diagnosed cancer and the sixth leading 
cause of cancer death among males worldwide, representing the most common form of 
cancer and the third cause of cancer-related death in men in developed countries [1]. 
Currently, PCa management and treatment is decided based on serum PSA levels, 
histopathological tumor characteristics and patient’s life expectancy, among other factors 
[12]. However, PCa behavior is frequently unpredictable, ranging from indolent, in which 
active surveillance might be the best choice, to highly aggressive, in which case radical 
treatment is required [23]. On the other hand, organ-confined PCa is mostly curable, in 
contrast to locally or systemically advanced disease, for which no effective curative 
treatments are available [12]. Due to the current inability to distinguish tumors that will 
remain indolent from those that will be lethal, physicians and patients tend to elect 
treatments with curative intent, but which lead to undesirable side-effects in a large 
proportion of patients [38]. The current methods for stratifying PCa tumors before patients’ 
treatment are based on PSA level, clinical stage (cTNM) and evaluation of Gleason score 
in biopsies samples as well as the number of cores / percentage of tissue that contain 
tumor cells [19,40]. Although all these clinical data are helpful, they cannot fully predict 
outcome or tumor aggressiveness [19,39]. Thus, a better characterization of tumor 
aggressiveness is critical for reducing both over-treatment and mortality due to this 
malignancy and it should be ideally based on the biological properties of PCa cells. 
 
EMT promotes cancer cell motility and the capacity to invade tissues and organs 
surrounding the tumor, as well as facilitates intravasation, allowing for metastasis 
formation at remote sites [43]. Hence, taking into account the important role of EMT in 
tumor progression, EMT-related genes might be used as markers of tumor progression, 
allowing for an improved assessment of tumor aggressiveness. Thus, we evaluated the 
transcript levels of EMT-related genes at different stages of prostate cancer progression, 
in an attempt to disclose new prognostic markers which might allow a better stratification 
of PCa patients according to the likelihood of progression to lethal forms of the disease. 
 
Firstly, we assessed the expression levels of 93 EMT-related genes using a 
RealTime ready Custom Panel 384 assay, using a limited series of prostatic tissues [NPT 
(n=5), pT2a+b-PCa (n=5), pT3b-PCa (n=5) and MET (n=5)], representing well defined 
stages of the disease. This assay allowed for the identification of five candidate genes: 
CAMK2N1, CD44, KRT14, TGFβ3 and WNT5A. Subsequently, the expression levels of 
these genes were further analyzed in a large independent series of samples. From these 
analyses, statistically significant differences in the expression levels of CAMK2N1, CD44 
and WNT5A among NPT, pT2a+b-PCa and pT3b-PCa were depicted, and these were 
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highest in the more advanced stage PCa cases. Thus, these gene panel constitutes a 
departing point for further exploitation of their potential as markers of clinically aggressive 
disease. 
 
CAMK2N1 encodes for a protein that inhibits CAMK2 activity, which has been 
implicated in cell cycle progression through activation of the MEK/ERK and Notch-1 
pathway [105,106]. As previously mentioned, Notch-1 and MEK/ERK pathways are both 
involved in EMT induction and, thus, CAMK2 proteins may play an important in EMT. In 
PCA cell lines, over-expression of CAMK2 was found to induce a decrease in apoptosis, 
whereas its inhibition reduces proliferation and invasion capacity [101]. Indeed, a recent 
study in PCa tissue samples has reported a higher expression of CAMK2N1 in PCa 
patients that recurred compared to patients in which no disease recurrence was detected 
after a five-year follow-up period [102]. Likewise, in our study, a significant increase in 
CAMK2N1 expression was observed in more advanced tumors (pT3b-PCa), supporting a 
correlation between CAMK2N1 expression and tumor progression, as well as, eventually, 
with EMT. However, because CAMK2 promotes proliferation and invasion, its inhibition in 
more advanced stages would not be expected. A possible explanation for this finding is 
that tumor cells actively engaged in EMT are usually less proliferative [73]. Thus, the 
inhibitory activity of CAMK2N1 on CAMK2 in PCa would provide conditions for cancer 
cells to endure EMT through slowing cell proliferative activity. However, the pathway 
through which CAMK2N1 expression promotes tumor aggressiveness remains unclear 
and there is a need to clarify which is the specific role of this gene in tumor progression. 
CD44 is a transmembrane glycoprotein involved in cell adhesion, migration, 
differentiation, signal transduction and apoptosis [98,107]. The extracellular domain of 
CD44 binds to numerous components of ECM, especially to hyaluronic acid (HA), 
whereas the intracytoplasmatic domain interacts with cytoskeletal proteins and 
intracellular signaling proteins [108]. Several studies have been undertaken to clarify the 
role of CD44 in PCa progression, and most have suggested that decreased, albeit 
variable, CD44 expression is associated with PCa progression. Indeed, a strong 
correlation between Gleason score and the loss of CD44 expression has been reported 
[109,110], but that is not a consensual finding [111]. Although, some studies suggested a 
tumor suppressive function for CD44 [99,110], others have implicated CD44 in PCa cell 
migration and invasion in vitro as well as in metastatic dissemination in vivo and 
chemoresistance [71,100,112]. Thus, both a tumor suppressive or an oncogenic function 
have been proposed for CD44, and the actual role of CD44 in PCa progression is still 
unclear. Our data favors an oncogenic function, since higher expression levels were found 
in more advanced and less differentiated tumors. Furthermore, CD44 has been recently 
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proposed as a CSC marker, namely for PCa stem cells [71]. These cells, as previously 
referred, play a central role in tumor progression, particularly for metastasis formation. 
Thus increased CD44 expression in more advanced tumors, as observed in our study, 
may be correlated with an increase of CSCs in these tumors, compared to early stage 
disease. Indeed, the increase of CSCs populations in these tumors may be one of the 
explanations for there more aggressive behavior. Nevertheless, this increase of CD44 
expression may also be seen as the results of an increase of CSCs induced by EMT.  
Taking into account the role of CD44 in cell adhesion and migration, the alteration 
of expression found in this study might reflect alterations in cell mobility. Although CD44 
was originally identified as a receptor for HA, there is evidence indicating that the binding 
to HA does not promote CD44-mediated cell migration and metastasis [113,114]. Later 
studies revealed thatt CD44 had affinity for other ligands, such as matrix 
metalloproteinase 9 (MMP9) [115]. Matrix metaloproteinases are essential for migration 
through the EMC and have a crucial role in ECM degradation, allowing cells to detach and 
migrate [116]. Previous studies have demonstrated that CD44 functions as a docking 
molecule for MMP9 on the cell surface, suggesting a mechanism for CD44-mediated cell 
migration and metastasis [100,115]. In this context, if the increased expression of CD44 in 
more aggressive tumor that we observed might be associated with an increased 
expression of MMP9, which could foster cell migration and subsequent invasion and 
metastasis formation in prostate cancer. 
Surprisingly, no differences were observed in CD44 expression levels between 
NPT and pT2a+b-PCa or pT3b-PCa, although our results suggest a decrease in CD44 
expression in pT2a+b-PCa and an increase in pT3b-PCa samples, when compared to 
NPT. It is likely that these results are due to the relatively small number of cases analyzed 
(especially NPT), which jeopardizes statistical significance. 
 
WNT5A is a member of Wnt family, implicated in tumor progression and 
osteomimicky (a process in which prostate cancer cells acquire an osteoblast-like 
phenotype) [117]. Thus, WNT5A may play an important role in PCa metastization since 
this cancer has a strong propensity to metastasize to bone. Indeed, a recent study 
showed a significant increase in WNT5A expression in advanced metastatic disease 
compared to benign prostatic lesions or early stage PCa [103]. However, significant 
differences between earlier disease stages were not reported [103]. Herein, WNT5A was 
stage-dependently expressed, showing a significant increase of expression along tumor 
stage. Surprisingly, WNT5A expression was significantly decreased in organ confined 
disease when compared to NPT, and no significant differences were observed between 
pT3b-PCa and NPT. These observations may indicate that suppression of WNT5A in 
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tumors renders them less aggressive and that when expression is kept they may acquire 
a more aggressive behavior.  
WNT5A is a non-canonical ligand which can activate the non-canonical Wnt 
pathway (Wnt/Ca2+), although it has been suggested that WNT5A may also interact with 
the canonical pathway (Wnt/β-catenin), which has been associated with tumor 
progression and stemness features [118].CD44 is one of the target genes of the Wnt/β-
catenin pathway and, interestingly, we found that the variation of expression observed for 
WNT5A was similar to that of CD44 [119]. This fact suggests a link between WNT5A 
expression and Wnt/β-catenin pathway activation in PCa. 
 
Concerning correlations between gene expression levels and standard 
clinicopathologic parameters, increased expression of CAMK2N1, CD44 and WNT5A, 
was associated with increased Gleason score, which is indicative of more aggressive 
disease. The Gleason score may also be considered a morphological marker of EMT, 
since the increase in the score is associated with the loss of epithelial glandular features 
and an increase of invasiveness. From this point of view, because WNT5A and CAMK2N1 
displayed the strongest correlations with the Gleason score, it is suggested that they 
might play an important role in EMT and, consequently, in the metastasis formation 
process of PCa.  
 
On the other hand, no correlation was found between expression levels and 
pathological stage or Gleason score for KRT14 and TGFβ3.  
TGFβ signaling has been reported as a signaling pathway involved in the EMT 
activation [43,46]. TGFβ3 encodes one of the ligands that, through the binding to the 
TGFβ receptor, can activate this signaling pathway [49]. Thus, in the context of TGFβ 
signaling as an inducer of cell migration an invasion, and increased expression of 
activators, like TGFβ3, would be expected. The TGF-β proteins are released in an inactive 
form to the ECM, where they are sequestered [120,121]. Thus, ECM acts as a reservoir 
from which inactive TGF-β proteins  can readily be activated without the need for new 
synthesis [49]. This fact may be one of the explanations for ours results, because the 
induction of EMT through TGFβ signaling may not require an increased expression of 
TGFB proteins, but only the activation of already synthesized proteins. 
 Keratins are a major component of epithelial cells cytoskeleton and play an 
important functional role in the integrity and mechanical stability of these cells [104]. 
During EMT, epithelial cells progressively loose expression of typical epithelial markers, 
such as keratins, and, thus, decreased expression with with tumor stage and Gleason 
score would be expected [43]. However, it has been reported that epithelial tumors largely 
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maintain the features of specific keratin expression associated with the respective cell 
type origin and, moreover, the expression spectrum of KRT14 in tumors is similar to that 
of the native normal epithelium, thus supporting our results [104].  
 
Concerning the preliminary results of the screening of expression of the 93 EMT-
related genes and the results of the posterior validation, some inconsistency between the 
results of the two assays was apparent. For CD44, an increase of expression with tumor 
stage was observed in the second analysis, contrarily to the results of the first assay, 
whereas for TGFB3 and KRT14, in the second analysis, no significant differences in 
expression between the different groups of samples were observed. These discrepancies 
are probably due to de number of samples analyzed: in the first analysis the number of 
samples analyzed was rather small, which may jeopardize the results. However, a 
screening of expression of 93 genes in a larger series of samples would be unaffordable. 
 
Although the expression analysis performed provided information about the 
amount of mRNA encoded by the selected genes, there is a need to verify the functional 
impact in terms of protein synthesis. The importance of this evaluation is mainly due to the 
fact that some epigenetic post-transcriptional regulation may occur and affect mRNA, 
eventually having no impact in protein expression. In addition, the identification of the 
mechanisms involved in deregulated gene expression regulation is also critical. 
 
Because PIN represents a precursor, non-invasive, lesion of PCa, we also 
evaluated the expression levels of the five EMT-related genes in PIN samples. Our 
expectations were that expression levels would be lower than those o PCa and, 
eventually, higher than those of NPT. However, the results of these analyses were mostly 
inconsistent, probably reflecting a substantial heterogeneity in the malignant potential of 
these precursor lesions. Indeed, it became clear over the last decade that albeit 
morphologically similar, PIN lesions do not harbor equal potential for progression to 
invasive carcinoma [122]. Thus, EMT-related gene expression heterogeneity might simply 
reflect different potential for developing an invasive phenotype. Expression levels of 
WNT5A in PIN samples were those that more closely followed the initial expectations, 
displaying a significant lower expression compared with pT3b-PCa, and thus supporting 
an association with tumor progression and invasion. 
 
In an attempt to increase the series of non-neoplastic samples, the evaluation of 
expression of the five selected genes was also performed in BPH samples. However, 
statistically significant differences in expression levels for the majority of analyzed genes 
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between the BPH and NPT samples were observed. We, thus, decided not to combine 
these two non-neoplastic groups of samples in the same series, excluding BPH samples 
from further analysis. A possible explanation for these results, is based on the fact that 
BPH and NPT samples, used in the present work, were collected from different regions of 
prostate: BPH samples were collected from the transition zone and NPT samples were 
collected from peripheral zone of prostate. Thus, the observed differences in gene 
expression might be due to the different anatomical origin of the samples. Interestingly, 
the diverse biological characteristics of anatomic prostate regions have been proposed as 
the main reason for the ,dissimilarities in gene expression between tumors located in the 
transition and peripheral zone of prostate previously reported [123]. On the other hand, it 
has been suggested that EMT may be involved in genesis of BPH, and some studies have 
already reported alterations in EMT-related genes in those lesions, which may further 
explain our results [124,125]. 
 
A major limitation of this preliminary study is that we assessed the expression of 
EMT-related genes in bulk tumor samples. EMT is a process that, when activated in 
carcinomas, does not occur in all cancer cells, but only in a variable, probably small 
proportion of them, which lead the invasion and metastization processes. Thus, the 
expression levels which represent an average of the tumor might not be representative of 
the cancer cells that undergo EMT. This may impair the detection of subtle differences in 
gene expression patterns which might be restricted to the invasive front of the tumor. To 
overcome this limitation, analysis of microdissected tumor cells is required.. However, if it 
holds true that more aggressive and advanced tumors are enriched in cells enduring EMT, 
then the significant differences in expression found for the selected genes between 
tumors with different grades of aggressiveness, are likely to reflect such differences in 
tumor cell subpopulations. Another limitation of this study was the inability to use data 
from metastasis of PCa. Because the available samples were obtained from formalin-
fixed, paraffin-embedded tissues, mRNA was of poor quality and it jeopardized the 
molecular assays. These are difficult tissue samples to obtain and the relevant information 
enclosed in metastatic tumor cells might be better revealed through immunohistochemical 
assays targeting the proteins encoded by the EMR-related genes. Evaluation of the 
expression of EMT-related genes in samples of metastases is likely to provide relevant 
data about the occurrence of MET during metastasis formation. 
 
 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
    
55 
Conclusion and Future Perspectives
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There is a current need to identify new biomarkers of PCa progression in an 
attempt to better discriminate indolent from aggressive tumors and thus improve patient 
management. Because EMT is associated with the acquisition of invasive and 
metastasizing behavior by tumor cells, which are features that denote tumor 
aggressiveness, we determined the expression of EMT-related genes in a series of PCa 
in an attempt to identify novel molecular markers of aggressive disease. 
 
Our results showed that three EMT-related genes - CAMK2N1, CD44 and WNT5A 
- were mostly overexpressed in more advanced and less differentiated PCa cases. Thus, 
they may constitute candidate biomarkers for the assessment of PCa clinical 
aggressiveness. 
 
The validation of these preliminary results will require the analysis of protein 
expression in routine tissue samples of PCa (e.g., biopsies) and a correlation with patient 
outcome. Immunohistochemistry is the obvious choice for that purpose as it constitutes, 
nowadays, a routine technique is most departments of Pathology. 
 
From a biological standpoint, to clarify the role of CAMK2N1 in PCa progression 
will require functional studies to determine the effectiveness of CAMK2 inhibition and the 
consequent effects in tumor cell phenotype.  
 
Finally, there is a need to better characterize the EMT-related genes concerning 
the mechanisms involved in gene expression regulation. Because EMT is a reversible 
process, and indeed this reversion seems to occur during metastasis formation, it is likely 
that epigenetic mechanisms are involved in both EMT and MET. The fact that some of 
these genes display CpG islands at their promoter region make then susceptible for 
regulation by methylation and this constitutes a starting point for further investigations of 
the plasticity and dynamics of EMT in PCa. 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
58 
 
 
 References
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
60 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
 
61 
 
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J 
Clin 61: 69-90. 
2. Ferlay J SH, Bray F, Forman D, Mathers C and Parkin DM. (2010) GLOBOCAN 2008 v1.2, Cancer 
Incidence and Mortality Worldwide. In: IARC CancerBase No. 10 L, editor. 
3. Giles G (2010) The Epidemiology of Prostate Cancer. In: Foulkes WDaC, K.A. , editor. Male 
Reproductive Cancers: Epidemiology, Pathology and Genetics. New York: Springer. pp. 3 
to 36. 
4. Bock CH, Schwartz AG, Ruterbusch JJ, Levin AM, Neslund-Dudas C, et al. (2009) Results from a 
prostate cancer admixture mapping study in African-American men. Hum Genet 126: 637-
642. 
5. Miller DC, Zheng SL, Dunn RL, Sarma AV, Montie JE, et al. (2003) Germ-line mutations of the 
macrophage scavenger receptor 1 gene: association with prostate cancer risk in African-
American men. Cancer Res 63: 3486-3489. 
6. Epstein JI (2009) Precursor lesions to prostatic adenocarcinoma. Virchows Arch 454: 1-16. 
7. Meyer F, Tetu B, Bairati I, Lacombe L, Fradet Y (2006) Prostatic intraepithelial neoplasia in TURP 
specimens and subsequent prostate cancer. Can J Urol 13: 3255-3260. 
8. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, et al. (2005) Prostate 
carcinogenesis and inflammation: emerging insights. Carcinogenesis 26: 1170-1181. 
9. Postma R, Schroder FH, van der Kwast TH (2005) Atrophy in prostate needle biopsy cores and 
its relationship to prostate cancer incidence in screened men. Urology 65: 745-749. 
10. Bostwick DG, Liu L, Brawer MK, Qian J (2004) High-grade prostatic intraepithelial neoplasia. 
Rev Urol 6: 171-179. 
11. Haggman MJ, Macoska JA, Wojno KJ, Oesterling JE (1997) The relationship between prostatic 
intraepithelial neoplasia and prostate cancer: critical issues. J Urol 158: 12-22. 
12. Damber JE, Aus G (2008) Prostate cancer. Lancet 371: 1710-1721. 
13. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, et al. (2011) [EAU guidelines on 
prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]. 
Actas Urol Esp 35: 501-514. 
14. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, et al. (2009) Mortality results from a 
randomized prostate-cancer screening trial. N Engl J Med 360: 1310-1319. 
15. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2009) Screening and 
prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328. 
16. van der Kwast TH, Lopes C, Santonja C, Pihl CG, Neetens I, et al. (2003) Guidelines for 
processing and reporting of prostatic needle biopsies. J Clin Pathol 56: 336-340. 
17. Epstein JI (2010) An update of the Gleason grading system. J Urol 183: 433-440. 
18. Eble JL, Sauter, G., . Epstein, J.L, Sesterhenn, I.A. (2004) World Health Organization and 
International Agency for Research of Cancer. Lyon: IARC. 
19. Bégin LR, Bismar, A.T. (2010) Prostate Cancer: A Pathological Perspective. In: Foulkes WDaC, 
K.A. , editor. Male Reproductive Cancers: Epidemiology, Pathology and Genetics. New 
York: Springer. 
20. Srigley JR, Amin M, Boccon-Gibod L, Egevad L, Epstein JI, et al. (2005) Prognostic and 
predictive factors in prostate cancer: historical perspectives and recent international 
consensus initiatives. Scand J Urol Nephrol Suppl: 8-19. 
21. Sobin L.H. WCH (2002) TNM classification of malignant tumours 6th edition. New York: Wiley-
Liss. 
22. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, et al. (2008) Systematic review: 
comparative effectiveness and harms of treatments for clinically localized prostate 
cancer. Ann Intern Med 148: 435-448. 
23. Moyer VA (2012) Screening for Prostate Cancer: U.S. Preventive Services Task Force 
Recommendation Statement. Ann Intern Med 157: 120-134. 
24. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management 
of clinically localized prostate cancer. JAMA 293: 2095-2101. 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
62 
25. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, et al. (2010) Clinical results of long-term follow-
up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28: 
126-131. 
26. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, et al. (2008) Radical prostatectomy 
versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer 
group-4 randomized trial. J Natl Cancer Inst 100: 1144-1154. 
27. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, et al. (2012) Radical prostatectomy 
versus observation for localized prostate cancer. N Engl J Med 367: 203-213. 
28. Jani AB, Hellman S (2003) Early prostate cancer: clinical decision-making. Lancet 361: 1045-
1053. 
29. Taira AV, Merrick GS, Butler WM, Galbreath RW, Lief J, et al. (2011) Long-term outcome for 
clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J 
Radiat Oncol Biol Phys 79: 1336-1342. 
30. Thompson IM, Jr., Leach RJ, Ankerst DP (2011) Prostate cancer detection: a view of the future. 
Eur Urol 59: 191-193. 
31. Miller AB (2012) New data on prostate-cancer mortality after PSA screening. N Engl J Med 
366: 1047-1048. 
32. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, et al. (2012) Prostate cancer 
screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening 
Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104: 125-132. 
33. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2012) Prostate-cancer 
mortality at 11 years of follow-up. N Engl J Med 366: 981-990. 
34. Lin K, Lipsitz R, Miller T, Janakiraman S (2008) Benefits and harms of prostate-specific antigen 
screening for prostate cancer: an evidence update for the U.S. Preventive Services Task 
Force. Ann Intern Med 149: 192-199. 
35. Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, et al. (2012) Short term outcomes of 
prostate biopsy in men tested for cancer by prostate specific antigen: prospective 
evaluation within ProtecT study. BMJ 344: d7894. 
36. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary 
treatment of localized prostate cancer. J Clin Oncol 28: 1117-1123. 
37. Chou R, Dana T, Bougatsos C, Fu R, Blazina I, et al. (2011) Treatments for Localized Prostate 
Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force 
Recommendation. Rockville (MD). 
38. Ganz PA, Barry JM, Burke W, Col NF, Corso PS, et al. (2012) National Institutes of Health State-
of-the-Science Conference: role of active surveillance in the management of men with 
localized prostate cancer. Ann Intern Med 156: 591-595. 
39. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, et al. (2011) The contemporary 
concept of significant versus insignificant prostate cancer. Eur Urol 60: 291-303. 
40. Bastian PJ, Mangold LA, Epstein JI, Partin AW (2004) Characteristics of insignificant clinical T1c 
prostate tumors. A contemporary analysis. Cancer 101: 2001-2005. 
41. Lee SE, Kim DS, Lee WK, Park HZ, Lee CJ, et al. (2010) Application of the Epstein criteria for 
prediction of clinically insignificant prostate cancer in Korean men. BJU Int 105: 1526-
1530. 
42. Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, et al. (2008) Validation of the contemporary 
epstein criteria for insignificant prostate cancer in European men. Eur Urol 54: 1306-1313. 
43. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 
119: 1420-1428. 
44. Kalluri R, Neilson EG (2003) Epithelial-mesenchymal transition and its implications for fibrosis. 
J Clin Invest 112: 1776-1784. 
45. Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of 
development and tumor metastasis. Dev Cell 14: 818-829. 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
 
63 
46. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 
442-454. 
47. Ouyang G, Wang Z, Fang X, Liu J, Yang CJ (2010) Molecular signaling of the epithelial to 
mesenchymal transition in generating and maintaining cancer stem cells. Cell Mol Life Sci 
67: 2605-2618. 
48. Jing Y, Han Z, Zhang S, Liu Y, Wei L (2011) Epithelial-Mesenchymal Transition in tumor 
microenvironment. Cell Biosci 1: 29. 
49. Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer 
progression. Nat Genet 29: 117-129. 
50. Tian M, Neil JR, Schiemann WP (2011) Transforming growth factor-beta and the hallmarks of 
cancer. Cell Signal 23: 951-962. 
51. Massague J (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169-178. 
52. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta 
family signalling. Nature 425: 577-584. 
53. Moustakas A, Heldin CH (2007) Signaling networks guiding epithelial-mesenchymal transitions 
during embryogenesis and cancer progression. Cancer Sci 98: 1512-1520. 
54. Min C, Eddy SF, Sherr DH, Sonenshein GE (2008) NF-kappaB and epithelial to mesenchymal 
transition of cancer. J Cell Biochem 104: 733-744. 
55. Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H, et al. (2010) NF-
kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic 
carcinoma cells. Cancer Lett 295: 214-228. 
56. Niessen K, Fu Y, Chang L, Hoodless PA, McFadden D, et al. (2008) Slug is a direct Notch target 
required for initiation of cardiac cushion cellularization. J Cell Biol 182: 315-325. 
57. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, et al. (2008) Cutaneous cancer stem 
cell maintenance is dependent on beta-catenin signalling. Nature 452: 650-653. 
58. Fan X, Matsui W, Khaki L, Stearns D, Chun J, et al. (2006) Notch pathway inhibition depletes 
stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 66: 7445-
7452. 
59. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, et al. (2011) Paracrine and autocrine signals 
induce and maintain mesenchymal and stem cell states in the breast. Cell 145: 926-940. 
60. Li LC, Zhao H, Nakajima K, Oh BR, Ribeiro Filho LA, et al. (2001) Methylation of the E-cadherin 
gene promoter correlates with progression of prostate cancer. J Urol 166: 705-709. 
61. Paterson EL, Kolesnikoff N, Gregory PA, Bert AG, Khew-Goodall Y, et al. (2008) The microRNA-
200 family regulates epithelial to mesenchymal transition. ScientificWorldJournal 8: 901-
904. 
62. Korpal M, Lee ES, Hu G, Kang Y (2008) The miR-200 family inhibits epithelial-mesenchymal 
transition and cancer cell migration by direct targeting of E-cadherin transcriptional 
repressors ZEB1 and ZEB2. J Biol Chem 283: 14910-14914. 
63. Zavadil J, Narasimhan M, Blumenberg M, Schneider RJ (2007) Transforming growth factor-beta 
and microRNA:mRNA regulatory networks in epithelial plasticity. Cells Tissues Organs 185: 
157-161. 
64. Pardal R, Clarke MF, Morrison SJ (2003) Applying the principles of stem-cell biology to cancer. 
Nat Rev Cancer 3: 895-902. 
65. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of 
evil in the war on cancer. Oncogene 29: 4741-4751. 
66. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that 
originates from a primitive hematopoietic cell. Nat Med 3: 730-737. 
67. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a cancer 
stem cell in human brain tumors. Cancer Res 63: 5821-5828. 
68. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective 
identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988. 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
64 
69. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, et al. (2007) Identification of a 
subpopulation of cells with cancer stem cell properties in head and neck squamous cell 
carcinoma. Proc Natl Acad Sci U S A 104: 973-978. 
70. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, et al. (2007) Identification of pancreatic cancer 
stem cells. Cancer Res 67: 1030-1037. 
71. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, et al. (2006) Highly purified 
CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic 
and metastatic progenitor cells. Oncogene 25: 1696-1708. 
72. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem 
cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 5: 744-749. 
73. Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, et al. (2011) Cancer stem cells in squamous 
cell carcinoma switch between two distinct phenotypes that are preferentially migratory 
or proliferative. Cancer Res 71: 5317-5326. 
74. Biddle A, Mackenzie IC (2012) Cancer stem cells and EMT in carcinoma. Cancer Metastasis 
Rev: 285-293. 
75. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. (2007) Distinct populations of 
cancer stem cells determine tumor growth and metastatic activity in human pancreatic 
cancer. Cell Stem Cell 1: 313-323. 
76. Tarin D, Thompson EW, Newgreen DF (2005) The fallacy of epithelial mesenchymal transition 
in neoplasia. Cancer Res 65: 5996-6000; discussion 6000-5991. 
77. Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Rep 50: 125-128. 
78. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI (1999) E-cadherin expression as a marker of 
tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 
53: 707-713. 
79. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG (1996) Expression of E-cadherin in 
primary and metastatic prostate cancer. Am J Pathol 148: 1375-1380. 
80. Saha B, Kaur P, Tsao-Wei D, Naritoku WY, Groshen S, et al. (2008) Unmethylated E-cadherin 
gene expression is significantly associated with metastatic human prostate cancer cells in 
bone. Prostate 68: 1681-1688. 
81. Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE, et al. (2010) N-cadherin increases 
after androgen deprivation and is associated with metastasis in prostate cancer. Endocr 
Relat Cancer 17: 469-479. 
82. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, et al. (2010) Monoclonal antibody 
targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration 
resistance. Nat Med 16: 1414-1420. 
83. Sethi S, Macoska J, Chen W, Sarkar FH (2010) Molecular signature of epithelial-mesenchymal 
transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 3: 90-99. 
84. Zhang Q, Helfand BT, Jang TL, Zhu LJ, Chen L, et al. (2009) Nuclear factor-kappaB-mediated 
transforming growth factor-beta-induced expression of vimentin is an independent 
predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 15: 
3557-3567. 
85. Chen H, Tu SW, Hsieh JT (2005) Down-regulation of human DAB2IP gene expression mediated 
by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 280: 
22437-22444. 
86. Xie D, Gore C, Liu J, Pong RC, Mason R, et al. (2010) Role of DAB2IP in modulating epithelial-to-
mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A 107: 
2485-2490. 
87. Zi X, Guo Y, Simoneau AR, Hope C, Xie J, et al. (2005) Expression of Frzb/secreted Frizzled-
related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate 
cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 65: 9762-
9770. 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
 
65 
88. Yee DS, Tang Y, Li X, Liu Z, Guo Y, et al. (2010) The Wnt inhibitory factor 1 restoration in 
prostate cancer cells was associated with reduced tumor growth, decreased capacity of 
cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol 
Cancer 9: 162. 
89. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, et al. (2010) FZD4 as a mediator of ERG oncogene-
induced WNT signaling and epithelial-to-mesenchymal transition in human prostate 
cancer cells. Cancer Res 70: 6735-6745. 
90. Zhu ML, Kyprianou N (2010) Role of androgens and the androgen receptor in epithelial-
mesenchymal transition and invasion of prostate cancer cells. FASEB J 24: 769-777. 
91. Beach S, Tang H, Park S, Dhillon AS, Keller ET, et al. (2008) Snail is a repressor of RKIP 
transcription in metastatic prostate cancer cells. Oncogene 27: 2243-2248. 
92. Alexander NR, Tran NL, Rekapally H, Summers CE, Glackin C, et al. (2006) N-cadherin gene 
expression in prostate carcinoma is modulated by integrin-dependent nuclear 
translocation of Twist1. Cancer Res 66: 3365-3369. 
93. Drake JM, Strohbehn G, Bair TB, Moreland JG, Henry MD (2009) ZEB1 enhances 
transendothelial migration and represses the epithelial phenotype of prostate cancer 
cells. Mol Biol Cell 20: 2207-2217. 
94. de Kok JB, Roelofs RW, Giesendorf BA, Pennings JL, Waas ET, et al. (2005) Normalization of 
gene expression measurements in tumor tissues: comparison of 13 endogenous control 
genes. Lab Invest 85: 154-159. 
95. Abruzzo LV, Lee KY, Fuller A, Silverman A, Keating MJ, et al. (2005) Validation of 
oligonucleotide microarray data using microfluidic low-density arrays: a new statistical 
method to normalize real-time RT-PCR data. Biotechniques 38: 785-792. 
96. Suzuki T, Higgins PJ, Crawford DR (2000) Control selection for RNA quantitation. Biotechniques 
29: 332-337. 
97. Biosystems A (2004) Guide to Performing Relative Quantitation of Gene Expression Using Real-
Time Quantitative PCR. Applied Biosystems. 
98. Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling 
regulators. Nat Rev Mol Cell Biol 4: 33-45. 
99. Gao AC, Lou W, Dong JT, Isaacs JT (1997) CD44 is a metastasis suppressor gene for prostatic 
cancer located on human chromosome 11p13. Cancer Res 57: 846-849. 
100. Desai B, Rogers MJ, Chellaiah MA (2007) Mechanisms of osteopontin and CD44 as metastatic 
principles in prostate cancer cells. Mol Cancer 6: 18. 
101. Rokhlin OW, Taghiyev AF, Bayer KU, Bumcrot D, Koteliansk VE, et al. (2007) 
Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell 
survival. Cancer Biol Ther 6: 732-742. 
102. Romanuik TL, Ueda T, Le N, Haile S, Yong TM, et al. (2009) Novel biomarkers for prostate 
cancer including noncoding transcripts. Am J Pathol 175: 2264-2276. 
103. Thiele S, Rauner M, Goettsch C, Rachner TD, Benad P, et al. (2011) Expression profile of WNT 
molecules in prostate cancer and its regulation by aminobisphosphonates. J Cell Biochem 
112: 1593-1600. 
104. Moll R, Divo M, Langbein L (2008) The human keratins: biology and pathology. Histochem 
Cell Biol 129: 705-733. 
105. Li N, Wang C, Wu Y, Liu X, Cao X (2009) Ca(2+)/calmodulin-dependent protein kinase II 
promotes cell cycle progression by directly activating MEK1 and subsequently modulating 
p27 phosphorylation. J Biol Chem 284: 3021-3027. 
106. Mamaeva OA, Kim J, Feng G, McDonald JM (2009) Calcium/calmodulin-dependent kinase II 
regulates notch-1 signaling in prostate cancer cells. J Cell Biochem 106: 25-32. 
107. Naor D, Sionov RV, Ish-Shalom D (1997) CD44: structure, function, and association with the 
malignant process. Adv Cancer Res 71: 241-319. 
108. Hao JL, Cozzi PJ, Khatri A, Power CA, Li Y (2010) CD147/EMMPRIN and CD44 are potential 
therapeutic targets for metastatic prostate cancer. Curr Cancer Drug Targets 10: 287-306. 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
66 
109. De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ (1998) CD44 and CD44v6 
downregulation in clinical prostatic carcinoma: relation to Gleason grade and 
cytoarchitecture. Prostate 34: 162-168. 
110. Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, et al. (1996) Decreased levels of CD44 
protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. 
Cancer 78: 1461-1469. 
111. Paradis V, Eschwege P, Loric S, Dumas F, Ba N, et al. (1998) De novo expression of CD44 in 
prostate carcinoma is correlated with systemic dissemination of prostate cancer. J Clin 
Pathol 51: 798-802. 
112. Hao J, Madigan MC, Khatri A, Power CA, Hung TT, et al. (2012) In Vitro and In Vivo Prostate 
Cancer Metastasis and Chemoresistance Can Be Modulated by Expression of either CD44 
or CD147. PLoS One 7: e40716. 
113. Sleeman JP, Arming S, Moll JF, Hekele A, Rudy W, et al. (1996) Hyaluronate-independent 
metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. Cancer Res 56: 
3134-3141. 
114. Spessotto P, Rossi FM, Degan M, Di Francia R, Perris R, et al. (2002) Hyaluronan-CD44 
interaction hampers migration of osteoclast-like cells by down-regulating MMP-9. J Cell 
Biol 158: 1133-1144. 
115. Yu Q, Stamenkovic I (1999) Localization of matrix metalloproteinase 9 to the cell surface 
provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13: 35-48. 
116. Kleiner DE, Stetler-Stevenson WG (1999) Matrix metalloproteinases and metastasis. Cancer 
Chemother Pharmacol 43 Suppl: S42-51. 
117. Hall CL, Kang S, MacDougald OA, Keller ET (2006) Role of Wnts in prostate cancer bone 
metastases. J Cell Biochem 97: 661-672. 
118. Pukrop T, Binder C (2008) The complex pathways of Wnt 5a in cancer progression. J Mol Med 
(Berl) 86: 259-266. 
119. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, et al. (1999) Expression of CD44 in Apc 
and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154: 515-523. 
120. Taipale J, Saharinen J, Keski-Oja J (1998) Extracellular matrix-associated transforming growth 
factor-beta: role in cancer cell growth and invasion. Adv Cancer Res 75: 87-134. 
121. Oklu R, Hesketh R (2000) The latent transforming growth factor beta binding protein (LTBP) 
family. Biochem J 352 Pt 3: 601-610. 
122. Henrique R, Jeronimo C, Teixeira MR, Hoque MO, Carvalho AL, et al. (2006) Epigenetic 
heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal 
progression in prostate carcinogenesis. Mol Cancer Res 4: 1-8. 
123. Erbersdobler A, Huhle S, Palisaar J, Graefen M, Hammerer P, et al. (2002) Pathological and 
clinical characteristics of large prostate cancers predominantly located in the transition 
zone. Prostate Cancer Prostatic Dis 5: 279-284. 
124. Alonso-Magdalena P, Brossner C, Reiner A, Cheng G, Sugiyama N, et al. (2009) A role for 
epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc 
Natl Acad Sci U S A 106: 2859-2863. 
125. Lu T, Lin WJ, Izumi K, Wang X, Xu D, et al. (2012) Targeting androgen receptor to suppress 
macrophage-induced EMT and benign prostatic hyperplasia (BPH) development. Mol 
Endocrinol 26: 1707-1715. 
 
 
 Annex 1
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
ii 
Molecular Markers of Epithelial to Mesenchymal Transition in Prostate Cancer 
 
 
 
III 
Table 5- Characteristics of the of 93 EMT-related genes studied. 
Related Gene 
Function 
Gene 
Symbol 
Gene Full Name Other Functions 
 
Differentiation 
and 
Development 
AHNAK AHNAK nucleoprotein  
CD44 CD44 molecule (Indian blood 
group) 
Cell adhesion 
ERBB3 v-erb-b2 erythroblastic leukemia 
viral oncogene homolog 3 
cell proliferation and  cell 
adhesion 
MITF microphthalmia-associated 
transcription factor 
Transcription factor 
NODAL nodal growth differentiation factor cell proliferation and cell 
migration  
POU5F1 POU class 5 homeobox 1 Regulator of Wnt pathway 
PROM1 prominin 1  
RARB retinoic acid receptor beta cell proliferation 
RGS2 regulator of G-protein signaling 2 cell proliferation 
SOX10 SRY (sex determining region Y)-
box 10 
cell proliferation, cell 
morphogenesis and regulator 
of Wnt pathway 
TCF3 transcription factor 3 transcription factor 
TCF4 transcription factor 4 transcription factor 
TMEFF1 transmembrane protein with EGF-
like and two follistatin-like domains 
1 
 
TMEM132A transmembrane protein 132A  
TWIST1  twist basic helix-loop-helix 
transcription factor 1 
Transcription factor 
 
Morphogenesis 
SNAI1 snail homolog 1 (Drosophila) Cell differentiation and cell 
migration 
SPARC secreted protein, acidic, cysteine-
rich (osteonectin) 
Extracellular matrix 
organization and cell migration 
 
Cell Growth and 
Proliferation 
AKT1  v-akt murine thymoma viral 
oncogene homolog 1 
Cell differentiation 
CAV2 caveolin 2 Cell migration 
EGFR epidermal growth factor receptor Cell migration and  cell 
adhesion 
FGFBP1 fibroblast growth factor binding 
protein 1 
Cell differentiation  and cell 
migration 
IGFBP4 insulin-like growth factor binding 
protein 4 
 
ILK integrin-linked kinase Cell adhesion, cell migration 
and regulation of Wnt pathway 
NKX3-1 NK3 homeobox 1  
PDGFRB platelet-derived growth factor 
receptor, beta polypeptide 
Cell migration and 
differentiation 
PTP4A1 protein tyrosine phosphatase type 
IVA, member 1 
Cell differentiation and cell 
migration 
RASSF1 Ras association (RalGDS/AF-6) 
domain family member 1 
 
ZEB1 zinc finger E-box binding homeobox 
1 
Cell differentiation and 
transcription factor 
 
Migration and 
Motility 
 
CALD1 caldesmon 1  
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Related Gene 
Function 
Gene 
Symbol 
Gene Full Name Other Functions 
 
Migration and 
Motility 
 
MSN moesin  
MST1R macrophage stimulating 1 receptor Cell differentiation, cell 
proliferation  
STAT3  signal transducer and activator of 
transcription 3 
Cell proliferation and 
regulation of Notch pathway 
TSPAN13 tetraspanin 13 Cell growth 
VIM vimentin cytoskeleton organization 
 
Cytoskeleton 
organization 
KRT7 keratin 7 Cell differentiation 
KRT14 keratin 14 Cell differentiation, cell 
adhesion 
KRT19 keratin 19 Cell differentiation 
MAP1B microtubule-associated protein 1B  
PLEK2 pleckstrin 2  
 
Extracellular 
Matrix and Cell 
Adhesion 
 
 
 
CDH1 cadherin 1, type 1, E-
cadherin (apithelial) 
 
CDH11 cadherin 11, type 2, OB-cadherin 
(osteoblast) 
 
CDH2 cadherin 2, type 1, N-cadherin 
(neuronal) 
 
CDH3 cadherin 3, type 1, P-cadherin 
(placental) 
 
COL1A2 collagen, type I, alpha 2  
COL5A2 collagen, type V, alpha 2  
DSC2 desmocollin 2  
DSP  desmoplakin cytoskeleton organization 
FN1 fibronectin 1 Cell migration and cell 
morphogenesis 
ITGA5 integrin, alpha 5   
ITGAV integrin, alpha V Cell proliferation and cell 
migration 
ITGB1 integrin, beta 1 cell migration 
MMP2 matrix metallopeptidase 2   
MMP3 matrix metallopeptidase 3  
MMP9 matrix metallopeptidase 9  cell proliferation 
OCLN occludin  
PTK2 protein tyrosine kinase 2 Cell proliferation and cell 
migration 
SERPINE1 serpin peptidase inhibitor, clade E Cell migration 
SPP1 secreted phosphoprotein 1  
STEAP1 six transmembrane epithelial 
antigen of the prostate 1 
Cell adhesion 
TFPI2 tissue factor pathway inhibitor 2  
TIMP1  TIMP metallopeptidase inhibitor 1 Cell proliferation and cell 
migration 
VCAN versican Cell proliferation and migration 
 
Signaling 
Pathways Notch 
FOXC2  forkhead box C2  Cell differentiation, cell 
proliferation, cell adhesion 
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V 
Related Gene 
Function 
Gene 
Symbol 
Gene Full Name Other Functions 
 
Signaling 
Pathways Notch 
 
JAG1 jagged 1 Cell differentiation, cell 
morphogenesis 
NOTCH1 notch 1 Cell differentiation, cell 
morphogenesis 
 
Signaling 
Pathways TGFβ  
BMP1 bone morphogenetic protein 1 Cell differentiation, 
extracellular matrix 
organization 
BMP7 bone morphogenetic protein 7 Cell differentiation, cell 
proliferation 
COL3A1 collagen, type III, alpha 1 Extracellular matrix 
organization 
F11R F11 receptor Cell differentiation, cell 
adhesion 
SMAD2 SMAD family member 2 Cell differentiation, cell 
proliferation, cell 
morphogenesis  
SMAD4 SMAD family member 4 Cell differentiation, cell 
morphogenesis 
TGFB1 transforming growth factor, beta 1 Cell proliferation, cell 
migration, cell adhesion 
TGFB2 transforming growth factor, beta 2 Cell differentiation, cell 
proliferation, cell 
morphogenesis, cell migration, 
cell adhesion 
TGFB3 transforming growth factor, beta 3 Cell differentiation, cell 
proliferation, cell adhesion 
 
Signaling 
Pathways Wnt 
 
CTNNB1 catenin (cadherin-associated 
protein), beta 1 
Cell morphogenesis,  cell 
proliferation, cell adhesion, 
cell-extracellular matrix 
adhesion and WNT pathway 
DAB2IP DAB2 interacting protein Cell proliferation, cell 
migrations 
FZD7 frizzled family receptor 7 Cell differentiation, stem cell 
division, stem cell 
maintenance 
GSC goosecoid homeobox Cell differentiation and Wnt 
pathway 
GSK3B glycogen synthase kinase 3 beta Cell proliferation, cell migration 
RAC1 ras-related C3 botulinum toxin 
substrate 1 
Cell morphogenesis, cell 
adhesion, cell-extracellular 
matrix adhesion, cytoskeleton 
organization and Wnt pathway 
SFRP1 secreted frizzled-related protein 1  
SNAI2 snail homolog 2 (Drosophila) Cell differentiation, stem cell 
proliferation, Notch pathway 
WNT11 wingless-type MMTV integration 
site family, member 11 
Cell differentiation, cell 
proliferation, cell migration 
WNT5A wingless-type MMTV integration 
site family, member 5A 
Cell differentiation  
WNT5B wingless-type MMTV integration 
site family, member 5B 
Cell differentiation, cell 
migration 
 
Other functions 
CAMK2N1 calcium/calmodulin-dependent 
protein kinase II inhibitor 1 
Calcium-dependent protein 
kinase inhibition 
GNG11 guanine nucleotide binding protein 
(G protein), gamma 11 
Modulation/transduction of 
transmembrane signaling 
IL1RN interleukin 1 receptor antagonist Modulation of immune and 
inflammatory responses 
NUDT13 nudix (nucleoside diphosphate 
linked moiety X)-type motif 13 
mitochondrial NADH 
diphosphatase 
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VI 
Related Gene 
Function 
Gene 
Symbol 
Gene Full Name Other Functions 
 
Other functions 
SIP1 survival motor neuron interacting 
protein 1  
Transcription factor 
SNAI3 snail homolog 3 (Drosophila) Transcription factor 
VPS13A vacuolar protein sorting 13 homolog 
A (S. cerevisiae) 
Proteins transport 
ZEB2 zinc finger E-box binding homeobox 
2 
Transcription factor 
Based on information available in http://www.ncbi.nlm.nih.gov/ 
 Annex 2
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IX 
Table 6- Results from Screening of 93 EMT related genes expression, 2
-ΔΔCt
. 
elated Gene 
Function 
Gene 
Symbol 
2
-ΔΔCt
 
pT3b-PCa vs. NPT pT3b-PCa vs pT2a+b-PCa 
 
Differentiation 
and 
Development 
AHNAK 0,82 0,6 
CD44 0,16 0,31 
ERBB3 2,11 0,76 
MITF 0,8 0,78 
NODAL n.a. n.a. 
POU5F1 0,39 1,13 
PROM1 0,14 0,38 
RARB 0,62 0,64 
RGS2 0,54 0,58 
SOX10 n.a. n.a. 
TCF3 1,78 1,72 
TCF4 0,68 0,45 
TMEFF1 1,23 1,57 
TMEM132A 2,58 1,32 
TWIST1  6,8 0,86 
 
Morphogenesis 
SNAI1 0,28 1,19 
SPARC 1,77 2,91 
 
Cell Growth and 
Proliferation 
AKT1  1,73 1,01 
CAV2 0,6 0,81 
EGFR 0,35 0,76 
FGFBP1 n.a. n.a. 
IGFBP4 0,82 1,29 
ILK 0,82 0,9 
NKX3-1 4,01 1 
PDGFRB 0,53 1,92 
PTP4A1 1,31 1,25 
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X 
elated Gene 
Function 
Gene 
Symbol 
2
-ΔΔCt
 
pT3b-PCa vs. NPT pT3b-PCa vs pT2a+b-PCa 
 
Cell Growth and 
Proliferation 
 
RASSF1 0,94 1,08 
ZEB1 0,77 0,66 
 
Migration and 
Motility 
 
 
 
 
CALD1 0,4 0,59 
MSN 0,74 1,35 
MST1R n.a. n.a. 
STAT3  1,02 0,88 
TSPAN13 5,39 1,24 
VIM 0,73 1,11 
 
Cytoskeleton 
organization 
KRT7 0,17 0,71 
KRT14 0,19 0,28 
KRT19 0,83 1,13 
MAP1B 0,58 1,81 
PLEK2 0,97 0,66 
 
Extracellular 
Matrix and Cell 
Adhesion 
 
 
 
CDH1 1,33 0,7 
CDH11 1,41 1,52 
CDH2 0,66 1,39 
CDH3 0,37 0,95 
COL1A2 1,12 5,26 
COL5A2 2,66 3,11 
DSC2 6,08 0,86 
DSP  1 0,84 
FN1 0,58 1,38 
ITGA5 0,21 0,65 
ITGAV 1,66 0,9 
ITGB1 0,96 0,79 
MMP2 0,5 1,56 
MMP3 n.a. n.a. 
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XI 
elated Gene 
Function 
Gene 
Symbol 
2
-ΔΔCt
 
pT3b-PCa vs. NPT pT3b-PCa vs pT2a+b-PCa 
 
Extracellular 
Matrix and Cell 
Adhesion 
 
MMP9 0,65 0,23 
OCLN 8,63 1,55 
PTK2 1,37 0,93 
SERPINE1 0,85 1,63 
SPP1 2,53 0,43 
STEAP1 3,58 0,72 
TFPI2 0,7 0,78 
TIMP1  1,31 0,99 
VCAN 2,69 5,94 
 
Signaling 
Pathways Notch 
 
FOXC2  0,55 1,02 
JAG1 1,29 1,53 
NOTCH1 0,4 1,38 
 
Signaling 
Pathways TGFβ  
BMP1 0,23 0,93 
BMP7 0,42 0,6 
COL3A1 1,54 2,31 
F11R 1,04 0,93 
SMAD2 1,81 0,92 
SMAD4 0,99 0,63 
TGFB1 0,79 1,87 
TGFB2 0,46 1,02 
TGFB3 0,21 0,26 
 
Signaling 
Pathways Wnt 
 
CTNNB1 1,25 0,73 
DAB2IP 0,3 0,78 
FZD7 0,49 1,27 
GSC 0,69 1,68 
GSK3B 2,31 0,91 
RAC1 1,83 1,16 
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XII 
elated Gene 
Function 
Gene 
Symbol 
2
-ΔΔCt
 
pT3b-PCa vs. NPT pT3b-PCa vs pT2a+b-PCa 
 
Signaling 
Pathways Wnt 
 
SFRP1 1,59 1,33 
SNAI2 0,17 0,54 
WNT11 0,49 2,91 
WNT5A 2,68 9,16 
WNT5B 0,39 0,58 
 
Other functions 
CAMK2N1 4,76 4,04 
GNG11 1,03 0,54 
IL1RN 0,82 2,13 
NUDT13 n.a. n.a. 
SIP1 1,63 1,01 
SNAI3 0,13 0,94 
VPS13A 1,99 1,52 
ZEB2 0,46 0,71 
Abbreviations: not available (n.a.) 
 
 
 
